U.S. patent application number 14/452116 was filed with the patent office on 2015-03-12 for anti-malarial compounds.
The applicant listed for this patent is Cellceutix Corporation. Invention is credited to Xiaodong Fan, Doron Greenbaum, Ehab Khalil, Dahui Liu, Richard W. Scott, Haizhong Tang, Yongjiang Xu.
Application Number | 20150072997 14/452116 |
Document ID | / |
Family ID | 41610687 |
Filed Date | 2015-03-12 |
United States Patent
Application |
20150072997 |
Kind Code |
A1 |
Scott; Richard W. ; et
al. |
March 12, 2015 |
ANTI-MALARIAL COMPOUNDS
Abstract
The present invention provides tricyclic compounds, arylamide
compounds, and other compounds, and compositions comprising the
same, for treating malaria, and methods of treating malaria
comprising administering such compounds to an animal.
Inventors: |
Scott; Richard W.; (Radnor,
PA) ; Greenbaum; Doron; (Philadelphia, PA) ;
Liu; Dahui; (Wynnewood, PA) ; Fan; Xiaodong;
(Center Valley, PA) ; Xu; Yongjiang; (Wayne,
PA) ; Tang; Haizhong; (Lawrenceville, NJ) ;
Khalil; Ehab; (Whitehouse Station, NJ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Cellceutix Corporation |
Beverly |
MA |
US |
|
|
Family ID: |
41610687 |
Appl. No.: |
14/452116 |
Filed: |
August 5, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12510593 |
Jul 28, 2009 |
8796275 |
|
|
14452116 |
|
|
|
|
61162467 |
Mar 23, 2009 |
|
|
|
61083972 |
Jul 28, 2008 |
|
|
|
Current U.S.
Class: |
514/256 ;
544/335 |
Current CPC
Class: |
C07D 295/135 20130101;
C07C 317/22 20130101; C07C 217/90 20130101; A61P 31/00 20180101;
C07D 335/12 20130101; C07D 207/12 20130101; C07D 295/096 20130101;
C07C 323/44 20130101; C07C 323/42 20130101; A61P 33/06 20180101;
C07D 239/28 20130101; C07D 333/76 20130101 |
Class at
Publication: |
514/256 ;
544/335 |
International
Class: |
C07D 239/28 20060101
C07D239/28 |
Claims
1-224. (canceled)
225. A compound of Formula V: ##STR00289## wherein: each X is,
independently, O, S, or S(.dbd.O).sub.2; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H,
C.sub.1-C.sub.3alkyl, or --(CH.sub.2).sub.p--NH.sub.2, where each p
is, independently, 1 or 2; each R.sup.2 is, independently, H, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.2 is H, and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or a pharmaceutically acceptable salt
thereof; provided that the compound is not: ##STR00290##
226. The compound or salt of claim 225 wherein each X is S.
227. The compound or salt of claim 225 wherein each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 or 2, and each R.sup.4 is, independently, H or
methyl.
228-230. (canceled)
231. The compound or salt of claim 225 wherein each R.sup.2 is,
independently, H, Br, F, Cl, CF.sub.3, or C(CH.sub.3).sub.3.
232. (canceled)
233. The compound or salt of claim 225 wherein each V.sup.2 is H
and each V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where
each R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
234-236. (canceled)
237. The compound or salt of claim 225 wherein each V.sup.1 is H
and each V.sup.2 is, independently, --S--R.sup.5, where each
R.sup.5 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
238. (canceled)
239. The compound or salt of claim 225 wherein each V.sup.1 is H
and each V.sup.2 is, independently, --S--R.sup.5, where each
R.sup.5 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2.
240. (canceled)
241. The compound or salt of claim 225 wherein: each X is S; each
R.sup.1 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 4.
242-246. (canceled)
247. The compound or salt of claim 225 wherein: each X is O or S;
each R.sup.1 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
each R.sup.2 is halo, CF.sub.3, or C(CH.sub.3).sub.3; and each
V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3, where
each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 3 or
4.
248. (canceled)
249. A compound chosen from: ##STR00291## ##STR00292## ##STR00293##
or a pharmaceutically acceptable salt thereof.
250. A composition comprising the compound or salt of claim 225 and
a pharmaceutically acceptable carrier.
251. A method of treating malaria in an animal or killing or
inhibiting the growth of a Plasmodium species comprising
administering to the animal a therapeutically effective amount of a
compound of Formula V or contacting the species with an effective
amount of a compound of Formula V: ##STR00294## wherein: each X is,
independently, O, S, or S(.dbd.O).sub.2; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H,
C.sub.1-C.sub.3alkyl, or --(CH.sub.2).sub.p--NH.sub.2, where each p
is, independently, 1 or 2; each R.sup.2 is, independently, H, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.2 is H, and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or a pharmaceutically acceptable salt
thereof.
252. The method of claim 251 wherein each X is S.
253. The method of claim 251 wherein each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 or 2, and each R.sup.4 is, independently, H or
methyl.
254-256. (canceled)
257. The method of claim 251 wherein each R.sup.2 is,
independently, H, Br, F, Cl, CF.sub.3, or C(CH.sub.3).sub.3.
258. (canceled)
259. The method of claim 251 wherein each V.sup.2 is H and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
260-262. (canceled)
263. The method of claim 251 wherein each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
264-266. (canceled)
267. The method of claim 251 wherein: each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 4.
268-272. (canceled)
273. The method of claim 251 wherein: each X is O or S; each
R.sup.1 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
each R.sup.2 is halo, CF.sub.3, or C(CH.sub.3).sub.3; and each
V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3, where
each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 3 or
4.
274. (canceled)
275. The method of claim 251 wherein the compound is chosen from:
##STR00295## ##STR00296## ##STR00297## or a pharmaceutically
acceptable salt thereof.
276. The method of claim 251 wherein the malaria is
chloroquine-sensitive or chloroquine-resistant.
277-375. (canceled)
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C.
.sctn.119(e) to U.S. provisional application Ser. No. 61/162,467
filed Mar. 23, 2009 and to U.S. provisional application Ser. No.
61/083,972 filed Jul. 28, 2008, each of which is incorporated
herein by reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention is directed, in part, to tricyclic
compounds, arylamide compounds, and other compounds, and
compositions comprising the same, for treating malaria, and methods
of treating malaria comprising administering such compounds to an
animal.
BACKGROUND OF THE INVENTION
[0003] World-wide, 41% of the population live in areas where
malaria is transmitted, such as parts of Africa, Asia, Middle East,
Central and South America, Hispaniola, and Oceania. Each year
between 350 and 500 million cases of malaria occur worldwide, and
over one million people die, most of them young children in
sub-Saharan Africa. In areas of Africa with high malaria
transmission, an estimated 990,000 people died of malaria in 1995.
In 2002, malaria was the fourth cause of death in children in
developing countries. In addition, malaria caused 10.7% of all
children's deaths in developing countries.
[0004] Antimicrobial peptides (AMPs) represent a component of the
innate immune system that provides resistance to a variety of
pathogenic bacteria. AMPs have provided new leads for developing
antibiotics, because they play a central role in the innate immune
system. Some AMPs display very broad spectrum action against
bacteria, yeast, fungus, and even viruses. Anti-parasitic
activities have also been reported for a number of host defense
peptides. The best studied organisms include Plasmodium,
Leishmania, and Trypanosoma (Vizioli et al., Trends in Pharmacol.,
2002, 18, 475-476; Jacobs et al., Antimicrob. Agents Chemother.,
2003, 47, 607-613; and Brand et al., J. Biol. Chem., 2002, 277,
49332-49340), the parasitic agents of malaria, leishmaniasis and
Chagas' disease, respectively. Additional protozoan parasites
reported to be killed by the host defense peptides are
Cryptosporidium (Giacometti et al., Antimicrob. Agents Chemother.,
2000, 44, 3473-3475) and Giardia (Aley et al., Infect. Immun.,
1994, 62, 5397-5403), human pathogens transmitted in contaminated
drinking water. The peptides appear to kill protozoa by interacting
with the cytoplasmic membrane causing excessive permeability, lysis
and death; a mechanism which is similar to their mechanism of
action against bacteria. Specificity for the parasite versus the
host cell can be attributed to differences in phospholipid content
and the lack of cholesterol in the protozoan membrane. Because the
site of action is at the membrane and not to any specific receptor
or intracellular target, the development of resistance to the
cytotoxic properties of the antimicrobial peptides is highly
unlikely.
[0005] With regard to anti-malarial activities, natural host
defense proteins and their analogs have been shown to inhibit
oocyst development of several Plasmodium species in various
mosquito hosts (Gwadz et al., Infect. Immun., 1989, 57, 2628-2633;
and Possani et al., Toxicon, 1998, 36, 1683-1692) and are directly
cytotoxic against early sporogonic stages of Plasmodium in cell
culture (Arrighi et al., Antimicrob. Agents Chemother., 2002, 46,
2104-2110). Furthermore, several antimicrobial peptides have been
identified which selectively kill intraerthrocytic parasites
(plasmodia life forms growing in red blood cells) by either
attacking the infected erythrocyte while sparring normal
erthrocytes (Feder et al., J. Biol. Chem., 2000, 275, 4230-4238;
and Krugliak et al., Antimicrob. Agents Chemother., 2000, 44,
2442-2451) or interacting with and killing the intracellular
parasite without harming the infected red blood cell (Dagan et al.,
Antimicrob. Agents Chemother., 2002, 46, 1059-1066; and Efron et
al., J. Biol. Chem., 2002, 277, 24067-24072). Recognizing the
significant therapeutic limitations of peptides, the development of
nonpeptidic mimics of these anti-plasmodia peptides would represent
a novel and powerful therapy to combat malaria.
SUMMARY OF THE INVENTION
[0006] The present invention provides compounds of Formula I:
##STR00001##
wherein: X is C(R.sup.7)C(R.sup.8), C(.dbd.O), N(R.sup.9), O, S,
S(.dbd.O), or S(.dbd.O).sub.2; R.sup.7, R.sup.8, and R.sup.9 are,
independently, H, C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy,
halo, OH, CF.sub.3, or aromatic group; R.sup.1 and R.sup.2 are,
independently, H, C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy,
halo, OH, haloC.sub.1-C.sub.8alkyl, or CN; R.sup.3 and R.sup.4 are,
independently, carbocycle(R.sup.5)(R.sup.6); each R.sup.5 and each
R.sup.6 are, independently, H, C.sub.1-C.sub.8alkyl,
C.sub.1-C.sub.8alkoxy, halo, OH, CF.sub.3, aromatic group,
heterocycle, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8; or a pharmaceutically acceptable salt
thereof, and compositions comprising the same and a
pharmaceutically acceptable carrier.
[0007] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula I:
##STR00002##
wherein: X is C(R.sup.2)C(R.sup.8), C(.dbd.O), N(R.sup.9), O, S,
S(.dbd.O), or S(.dbd.O).sub.2; R.sup.7, R.sup.8, and R.sup.9 are,
independently, H, C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy,
halo, OH, CF.sub.3, or aromatic group; R.sup.1 and R.sup.2 are,
independently, H, C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy,
halo, OH, haloC.sub.1-C.sub.8alkyl, or CN; R.sup.3 and R.sup.4 are,
independently, carbocycle(R.sup.5)(R.sup.6); each R.sup.5 and each
R.sup.6 are, independently, H, C.sub.1-C.sub.8alkyl,
C.sub.1-C.sub.8alkoxy, halo, OH, CF.sub.3, aromatic group,
heterocycle, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8; or a pharmaceutically acceptable salt
thereof.
[0008] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
I:
##STR00003##
wherein: X is C(R.sup.7)C(R.sup.8), C(.dbd.O), N(R.sup.9), O, S,
S(.dbd.O), or S(.dbd.O).sub.2; R.sup.7, R.sup.8, and R.sup.9 are,
independently, H, C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy,
halo, OH, CF.sub.3, or aromatic group; R.sup.1 and R.sup.2 are,
independently, H, C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy,
halo, OH, haloC.sub.1-C.sub.8alkyl, or CN; R.sup.3 and R.sup.4 are,
independently, carbocycle(R.sup.5)(R.sup.6); each R.sup.5 and each
R.sup.6 are, independently, H, C.sub.1-C.sub.8alkyl,
C.sub.1-C.sub.8alkoxy, halo, OH, CF.sub.3, aromatic group,
heterocycle, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8; or a pharmaceutically acceptable salt
thereof.
[0009] The present invention also provides compounds of Formula
II:
##STR00004##
wherein: X is O or S; each Y is, independently, O, S, or N; each
R.sup.1 is, independently, H, 5- or 6-membered heterocycle, or the
free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each R.sup.1 is, independently, together
with Y a 5- or 6-membered heterocycle; each R.sup.2 is,
independently, H, CF.sub.3, C(CH.sub.3).sub.3, halo, or OH; and
each R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or a pharmaceutically acceptable salt
thereof, and compositions comprising the same and a
pharmaceutically acceptable carrier.
[0010] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula II:
##STR00005##
wherein: X is O or S; each Y is, independently, O, S, or N; each
R.sup.1 is, independently, H, 5- or 6-membered heterocycle, or the
free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each R.sup.1 is, independently, together
with Y a 5- or 6-membered heterocycle; each R.sup.2 is,
independently, H, CF.sub.3, C(CH.sub.3).sub.3, halo, or OH; and
each R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or a pharmaceutically acceptable salt
thereof.
[0011] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
II:
##STR00006##
wherein: X is O or S; each Y is, independently, O, S, or N; each
R.sup.1 is, independently, H, 5- or 6-membered heterocycle, or the
free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each R.sup.1 is, independently, together
with Y a 5- or 6-membered heterocycle; each R.sup.2 is,
independently, H, CF.sub.3, C(CH.sub.3).sub.3, halo, or OH; and
each R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or a pharmaceutically acceptable salt
thereof.
[0012] The present invention also provides compounds of Formula
III:
Q-X--Z--X-Q
wherein: Z is
##STR00007##
or phenyl; each Q is, independently,
##STR00008##
or --C(.dbd.O)--(CH.sub.2).sub.b--NH--C(.dbd.NH)--NH.sub.2, where
each b is, independently, 1 to 4; each X is, independently, O, S,
or N; each R.sup.1 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH; each R.sup.3 is, independently, H,
--NH--R.sup.2, --(CH.sub.2).sub.r--NH.sub.2, --NH.sub.2,
--NH--(CH.sub.2).sub.w--NH.sub.2, or
##STR00009##
where each r is, independently, 1 or 2, each w is, independently, 1
to 3, and each y is, independently, 1 or 2; each R.sup.2 is,
independently, H, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.4 is, independently, H,
--NH--C(.dbd.O)--(CH.sub.2).sub.p--NH--C(.dbd.NH)--NH.sub.2 or
##STR00010##
where each p is, independently, 1 to 6, and each q is,
independently, 1 or 2; and each R.sup.5 is, independently, H or
CF.sub.3; or a pharmaceutically acceptable salt thereof, and
compositions comprising the same and a pharmaceutically acceptable
carrier.
[0013] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula III:
Q-X--Z--X-Q
wherein: Z is
##STR00011##
or phenyl; each Q is, independently,
##STR00012##
or --C(.dbd.O)--(CH.sub.2).sub.b--NH--C(.dbd.NH)--NH.sub.2, where
each b is, independently, 1 to 4; each X is, independently, O, S,
or N; each R.sup.1 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH; each R.sup.3 is, independently, H,
--NH--R.sup.2, --(CH.sub.2).sub.r--NH.sub.2, --NH.sub.2,
--NH--(CH.sub.2).sub.w--NH.sub.2, or
##STR00013##
where each r is, independently, 1 or 2, each w is, independently, 1
to 3, and each y is, independently, 1 or 2; each R.sup.2 is,
independently, H, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.4 is, independently, H,
--NH--C(.dbd.O)--(CH.sub.2).sub.p--NH--C(.dbd.NH)--NH.sub.2 or
##STR00014##
where each p is, independently, 1 to 6, and each q is,
independently, 1 or 2; and each R.sup.5 is, independently, H or
CF.sub.3, or a pharmaceutically acceptable salt thereof.
[0014] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
III:
Q-X--Z--X-Q
wherein: Z is
##STR00015##
or phenyl; each Q is, independently,
##STR00016##
or --C(.dbd.O)--(CH.sub.2).sub.b--NH--C(.dbd.NH)--NH.sub.2, where
each b is, independently, 1 to 4; each X is, independently, O, S,
or N; each R.sup.1 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH; each R.sup.3 is, independently, H,
--NH--R.sup.2, --(CH.sub.2).sub.r--NH.sub.2, --NH.sub.2,
--NH--(CH.sub.2).sub.w--NH.sub.2, or
##STR00017##
where each r is, independently, 1 or 2, each w is, independently, 1
to 3, and each y is, independently, 1 or 2; each R.sup.2 is,
independently, H, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.4 is, independently, H,
--NH--C(.dbd.O)--(CH.sub.2).sub.p--NH--C(.dbd.NH)--NH.sub.2 or
##STR00018##
where each p is, independently, 1 to 6, and each q is,
independently, 1 or 2; and each R.sup.5 is, independently, H or
CF.sub.3, or a pharmaceutically acceptable salt thereof.
[0015] The present invention also provides compounds of Formula
IV:
##STR00019##
wherein: G is
##STR00020##
each X is, independently, O or S; each R.sup.1 is,
independently,
##STR00021##
or the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, H,
C.sub.1-C.sub.8alkyl, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.3 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH; and each R.sup.4 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4, or a pharmaceutically acceptable salt
thereof, and compositions comprising the same and a
pharmaceutically acceptable carrier.
[0016] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula IV:
##STR00022##
wherein: G is
##STR00023##
each X is, independently, O or S; each R.sup.1 is,
independently,
##STR00024##
or the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, H,
C.sub.1-C.sub.8alkyl, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.3 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH; and each R.sup.4 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4, or a pharmaceutically acceptable salt
thereof.
[0017] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
IV:
##STR00025##
wherein: G is
##STR00026##
each X is, independently, O or S; each R.sup.1 is,
independently,
##STR00027##
or the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, H,
C.sub.1-C.sub.8alkyl, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.3 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH; and each R.sup.4 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4, or a pharmaceutically acceptable salt
thereof.
[0018] The present invention also provides compounds of Formula
V:
##STR00028##
wherein: each X is, independently, O, S, or S(.dbd.O).sub.2; each
R.sup.1 is, independently, --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.p--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H,
C.sub.1-C.sub.3alkyl, or --(CH.sub.2).sub.p--NH.sub.2, where each p
is, independently, 1 or 2; each R.sup.2 is, independently, H, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.2 is H, and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or a pharmaceutically acceptable salt
thereof, and compositions comprising the same and a
pharmaceutically acceptable carrier, provided that the compound is
not:
##STR00029##
[0019] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula V:
##STR00030##
wherein: each X is, independently, O, S, or S(.dbd.O).sub.2; each
R.sup.1 is, independently, --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.p--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H,
C.sub.1-C.sub.3alkyl, or --(CH.sub.2).sub.p--NH.sub.2, where each p
is, independently, 1 or 2; each R.sup.2 is, independently, H, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.2 is H, and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or a pharmaceutically acceptable salt
thereof.
[0020] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
V:
##STR00031##
wherein: each X is, independently, O, S, or S(.dbd.O).sub.2; each
R.sup.1 is, independently, --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H,
C.sub.1-C.sub.3alkyl, or --(CH.sub.2).sub.p--NH.sub.2, where each p
is, independently, 1 or 2; each R.sup.2 is, independently, H, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.2 is H, and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or a pharmaceutically acceptable salt
thereof.
[0021] The present invention also provides compounds of Formula
VI:
##STR00032##
wherein: each Y is, independently, O, S, or NH; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; and each R.sup.2 is, independently, H, halo,
CF.sub.3, or C(CH.sub.3).sub.3; or a pharmaceutically acceptable
salt thereof, and compositions comprising the same and a
pharmaceutically acceptable carrier.
[0022] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula VI:
##STR00033##
wherein: each Y is, independently, O, S, or NH; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; and each R.sup.2 is, independently, H, halo,
CF.sub.3, or C(CH.sub.3).sub.3; or a pharmaceutically acceptable
salt thereof.
[0023] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
VI:
##STR00034##
wherein: each Y is, independently, O, S, or NH; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; and each R.sup.2 is, independently, H, halo,
CF.sub.3, or C(CH.sub.3).sub.3; or a pharmaceutically acceptable
salt thereof.
[0024] The present invention also provides method of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula VII:
##STR00035##
wherein: each R.sup.1 is, independently, H, C.sub.1-C.sub.8alkyl,
C.sub.1-C.sub.8alkoxy, halo, OH, CF.sub.3, or CN; each R.sup.2 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or a pharmaceutically acceptable salt
thereof.
[0025] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
VII:
##STR00036##
wherein: each R.sup.1 is, independently, H, C.sub.1-C.sub.8alkyl,
C.sub.1-C.sub.8alkoxy, halo, OH, CF.sub.3, or CN; each R.sup.2 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or a pharmaceutically acceptable salt
thereof.
[0026] The present invention also provides compounds of Formula
VIII:
##STR00037##
wherein: D is
##STR00038##
each B is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4,
##STR00039##
and each X is, independently, O or S, or a pharmaceutically
acceptable salt thereof, and compositions comprising the same and a
pharmaceutically acceptable carrier.
[0027] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula VIII:
##STR00040##
wherein: D is
##STR00041##
each B is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4,
##STR00042##
and each X is, independently, O or S, or a pharmaceutically
acceptable salt thereof.
[0028] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
VIII:
##STR00043##
wherein: D is
##STR00044##
each B is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4,
##STR00045##
and each X is, independently, O or S, or a pharmaceutically
acceptable salt thereof.
DESCRIPTION OF EMBODIMENTS
[0029] Collectively and individually, each of the compounds
described herein are also referred to herein as "anti-malarial
compounds."
[0030] As used herein and unless otherwise indicated, the term
"animal" is intended to include, but not be limited to, humans and
non-human vertebrates such as wild, domestic and farm animals.
[0031] As used herein and unless otherwise indicated, the term
"about" is intended to mean.+-.5% of the value it modifies. Thus,
about 100 means 95 to 105.
[0032] As used herein and unless otherwise indicated, the term
"alkyl" is intended to include branched and straight-chain
saturated aliphatic hydrocarbon groups having the specified number
of carbon atoms. For example, C.sub.1-C.sub.8, as in
"C.sub.1-C.sub.8 alkyl" is intended to include groups having 1, 2,
3, 4, 5, 6, 7, or 8 carbons in a linear or branched arrangement.
"C.sub.1-C.sub.6 alkyl" is intended to include groups having 1, 2,
3, 4, 5, or 6 carbons in a linear or branched arrangement.
"C.sub.1-C.sub.3 alkyl" is intended to include groups having 1, 2,
or 3 carbons in a linear or branched arrangement. Examples of alkyl
groups include, but are not limited to, methyl, ethyl, n-propyl,
i-propyl, n-butyl, t-butyl, i-butyl, 2-methyl-1-propyl,
2-methyl-2-propyl, pentyl, 2-methyl-1-butyl, 3-methyl-1-butyl,
2-methyl-3-butyl, 2,2-dimethyl-1-propyl, isopentyl, neopentyl,
hexyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl,
2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl,
2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl,
heptyl, and octyl, or any combination thereof. An alkyl group can
be unsubstituted or substituted with one, two, or three suitable
substituents. These same alkyl groups can be used in connection
with "alkoxy" groups, "haloalkyl" groups, "alkenyl" groups,
"alkynyl" groups, and "cycloalkyl" groups as appropriate.
[0033] As used herein and unless otherwise indicated, the term
"halo" means fluorine, chlorine, bromine, or iodine.
[0034] As used herein and unless otherwise indicated, the phrase
"5- or 6-membered heterocycle" means a monocyclic ring comprising
carbon atoms, hydrogen atoms, and one or more heteroatoms, such as
1 to 3 heteroatoms, independently chosen from nitrogen, oxygen, and
sulfur. 5-membered heterocycles include, but are not limited to,
thienyl, 2-thienyl, 3-thienyl, furyl, 2-furyl, 3-furyl, pyrrolyl,
2-pyrrolyl, 3-pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl,
pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, and
pyrazolinyl. 6-membered heterocycles include, but are not limted
to, pyranyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl,
piperidyl, piperazinyl, and morpholinyl. The 5- and 6-membered
heterocycles can be unsubstituted or substituted with one, two, or
three suitable substituents.
[0035] As used herein and unless otherwise indicated, the phrase
"carbocycle" means a 5- or 6-membered, saturated or unsaturated
cyclic ring, optionally containing O, S, or N atoms as part of the
ring. Examples of carbocycles include, but are not limited to,
cyclopentyl, cyclohexyl, cyclopenta-1,3-diene, phenyl, and any of
the heterocycles recited above.
[0036] As used herein and unless otherwise indicated, the term
"phenyl" means --C.sub.6H.sub.5. A phenyl group can be
unsubstituted or substituted with one, two, or three suitable
substituents.
[0037] As used herein and unless otherwise indicated, the phrase
"therapeutically effective amount" of a composition or compound is
measured by the therapeutic effectiveness of the administered
compound, wherein at least one adverse effect is ameliorated or
alleviated. The therapeutic effect is dependent upon the disorder
being treated or the biological effect desired. As such, the
therapeutic effect can be a decrease in the severity of symptoms
associated with the disorder and/or inhibition (partial or
complete) of progression of the disorder, or improved treatment,
healing, prevention or elimination of a disorder, or side-effects.
The amount needed to elicit the therapeutic response can be
determined based on the age, health, size and sex of the subject.
Optimal amounts can also be determined based on monitoring of the
subject's response to treatment.
[0038] When administered to a mammal (e.g., to an animal for
veterinary use or to a human for clinical use) the anti-malarial
compounds described herein can be administered in isolated form. As
used herein and unless otherwise indicated, the term "isolated"
means that the anti-malarial compounds described herein are
separated from other components of either (a) a natural source,
such as a plant or cell, such as a bacterial culture, or (b) a
synthetic organic chemical reaction mixture, such as by
conventional techniques.
[0039] As used herein and unless otherwise indicated, the term
"purified" means that when isolated, the isolate contains at least
90%, at least 95%, at least 98%, or at least 99% of an
anti-malarial compound described herein by weight of the
isolate.
[0040] As used herein and unless otherwise indicated, the phrase
"pharmaceutically acceptable salt(s)," includes, but is not limited
to, salts of acidic or basic groups. Compounds that are basic in
nature are capable of forming a wide variety of salts with various
inorganic and organic acids. Acids that may be used to prepare
pharmaceutically acceptable acid addition salts of such basic
compounds are those that form non-toxic acid addition salts, i.e.,
salts containing pharmacologically acceptable anions including, but
not limited to, sulfuric, citric, maleic, acetic, oxalic,
hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate,
bisulfate, phosphate, acid phosphate, isonicotinate, acetate,
lactate, salicylate, citrate, acid citrate, tartrate, oleate,
tannate, pantothenate, bitartrate, ascorbate, succinate, maleate,
gentisinate, fumarate, gluconate, glucaronate, saccharate, formate,
benzoate, glutamate, methanesulfonate, ethanesulfonate,
benzenesulfonate, p-toluenesulfonate and pamoate (i.e.,
1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Compounds that
include an amino moiety may form pharmaceutically acceptable salts
with various amino acids, in addition to the acids mentioned above.
Compounds that are acidic in nature are capable of forming base
salts with various pharmacologically acceptable cations. Examples
of such salts include, but are not limited to, alkali metal or
alkaline earth metal salts and, particularly, calcium, magnesium,
sodium lithium, zinc, potassium, and iron salts.
[0041] As used herein and unless otherwise indicated, the phrase
"suitable substituent" means a group that does not nullify the
synthetic or pharmaceutical utility of the anti-malarial compounds
described herein or the intermediates useful for preparing them.
Examples of suitable substituents include, but are not limited to:
(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkenyl,
(C.sub.1-C.sub.6)alkynyl, (C.sub.5-C.sub.6)aryl,
(C.sub.3-C.sub.5)heteroaryl, (C.sub.3-C.sub.6)cycloalkyl,
(C.sub.1-C.sub.6)alkoxy, (C.sub.5-C.sub.6)aryloxy, --CN, --OH, oxo,
halo, --NO.sub.2, --CO.sub.2H, --NH.sub.2,
--NH((C.sub.1-C.sub.8)alkyl), --N((C.sub.1-C.sub.8)alkyl).sub.2,
--NH((C.sub.5-C.sub.6)aryl), --N((C.sub.5-C.sub.6)aryl).sub.2,
--CHO, --CO((C.sub.1-C.sub.6)alkyl), --CO((C.sub.5-C.sub.6)aryl),
--CO.sub.2((C.sub.1-C.sub.6)alkyl), and
--CO.sub.2((C.sub.5-C.sub.6)aryl). One of skill in art can readily
choose a suitable substituent based on the stability and
pharmacological and synthetic activity of the anti-malarial
compounds described herein.
[0042] As used herein and unless otherwise indicated, the terms
"treatment" or "treating" refers to an amelioration of malaria, or
at least one discernible symptom thereof. In another embodiment,
"treatment" or "treating" refers to an amelioration of at least one
measurable physical parameter, not necessarily discernible by the
patient. In yet another embodiment, "treatment" or "treating"
refers to inhibiting the progression of malaria, either physically,
e.g., stabilization of a discernible symptom, physiologically,
e.g., stabilization of a physical parameter, or both. In yet
another embodiment, "treatment" or "treating" refers to delaying
the onset of malaria.
[0043] In some embodiments, the anti-malarial compound, or
composition comprising the same, are administered to a patient,
such as a human, as a preventative measure against malaria. As used
herein and unless otherwise indicated, "prevention" or "preventing"
refers to a reduction of the risk of acquiring malaria.
[0044] The anti-malarial compounds described herein may contain one
or more chiral centers and/or double bonds and, therefore, exist as
stereoisomers, such as double-bond isomers (i.e., geometric
isomers), enantiomers, or diastereomers. Therefore, the
anti-malarial compounds described herein encompass all of the
corresponding compound's enantiomers and stereoisomers, that is,
both the stereomerically pure form (e.g., geometrically pure,
enantiomerically pure, or diastereomerically pure) and enantiomeric
and stereoisomeric mixtures. Enantiomeric and stereoisomeric
mixtures can be resolved into their component enantiomers or
stereoisomers by well known methods, such as chiral-phase gas
chromatography, chiral-phase high performance liquid
chromatography, crystallizing the compound as a chiral salt
complex, or crystallizing the compound in a chiral solvent.
Enantiomers and stereoisomers can also be obtained from
stereomerically- or enantiomerically-pure intermediates, reagents,
and catalysts by well known asymmetric synthetic methods.
[0045] The present invention provides compounds of Formula I:
##STR00046##
wherein:
[0046] X is C(R.sup.7)C(R.sup.8), C(.dbd.O), N(R.sup.9), O, S,
S(.dbd.O), or S(.dbd.O).sub.2;
[0047] R.sup.7, R.sup.8, and R.sup.9 are, independently, H,
C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy, halo, OH, CF.sub.3, or
aromatic group;
[0048] R.sup.1 and R.sup.2 are, independently, H,
C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy, halo, OH,
haloC.sub.1-C.sub.8alkyl, or CN;
[0049] R.sup.3 and R.sup.4 are, independently,
carbocycle(R.sup.5)(R.sup.6);
[0050] each R.sup.5 and each R.sup.6 are, independently, H,
C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy, halo, OH, CF.sub.3,
aromatic group, heterocycle, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8;
or a pharmaceutically acceptable salt thereof.
[0051] In some embodiments, X is N(R.sup.9), O, S, or
S(.dbd.O).sub.2; or X is NH, O, or S; or X is NH or S.
[0052] In any of the above embodiments, R.sup.1 and R.sup.2 are,
independently, H, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy,
halo, OH, haloC.sub.1-C.sub.3alkyl, or CN; or R.sup.1 and R.sup.2
are, independently, H, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy,
halo, or OH; or R.sup.1 and R.sup.2 are, independently, H,
C.sub.1-C.sub.3alkyl, or halo; or R.sup.1 and R.sup.2 are H.
[0053] In any of the above embodiments, R.sup.3 and R.sup.4 are,
independently, carbocycle(R.sup.5)(R.sup.6), where R.sup.5 and
R.sup.6 can be positioned anywhere on the carbocycle. In any of the
above embodiments, R.sup.3 and R.sup.4 are, independently,
##STR00047##
wherein each W, Y, and Z are, independently, C or N, each A, D, and
Q are, independently, C(R.sup.10)C(R.sup.11), C(.dbd.O),
N(R.sup.12), O, or S, and each R.sup.10, R.sup.11, and R.sup.12
are, independently, H, C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy,
halo, OH, CF.sub.3, or aromatic group.
[0054] In any of the above embodiments, R.sup.3 and R.sup.4 are,
independently,
##STR00048##
wherein each W, Y, and Z are, independently, C or N; or R.sup.3 and
R.sup.4 are, independently,
##STR00049##
wherein each W, Y, and Z are C, or each Y and Z are C and each W is
N.
[0055] In any of the above embodiments, each R.sup.5 is,
independently, H, C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy,
halo, OH, CF.sub.3, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8, and each R.sup.6 is, independently,
heterocycle or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8; or each R.sup.5 is, independently, H,
C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy, halo, OH, or CF.sub.3,
and each R.sup.6 is, independently, heterocycle or the free base or
salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 8; or each R.sup.5 is, independently, H,
C.sub.1-C.sub.3alkyl, halo, or OH; and each R.sup.6 is,
independently, heterocycle or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
4; or each R.sup.5 is, independently, H, C.sub.1-C.sub.3alkyl,
halo, or OH; and each R.sup.6 is, independently, 6-membered
heterocycle or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3; or each R.sup.5 is, independently, H or halo; and each R.sup.6
is piperazinyl or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 where each n is, independently, 1 to
3; or each R.sup.5 is piperazinyl; and each R.sup.6 is,
independently, H, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy,
halo, OH, or CF.sub.3; or each R.sup.5 is piperazinyl; and each
R.sup.6 is H, C.sub.1-C.sub.3alkyl, halo, OH, or CF.sub.3.
[0056] In some embodiments, X is NH, O, S, or S(.dbd.O).sub.2;
R.sup.1 and R.sup.2 are H; R.sup.3 and R.sup.4 are,
independently,
##STR00050##
wherein: each W, Y, and Z are, independently, C or N; each R.sup.5
and each R.sup.6 are, independently, H, heterocycle, or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 3.
[0057] In some embodiments, X is NH, O, or S; R.sup.1 and R.sup.2
are H; R.sup.3 and R.sup.4 are
##STR00051##
where each Z and Y are C, and each W is N; or each W, Y, and Z are
C; each R.sup.5 is, independently, H or halo, and each R.sup.6 is
piperazinyl or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3; or each R.sup.5 is piperazinyl, and each R.sup.6 is,
independently, H, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy,
halo, OH, or CF.sub.3.
[0058] In some embodiments, X is NH, O, or S; R.sup.1 and R.sup.2
are H; R.sup.3 and R.sup.4 are
##STR00052##
where each Z and Y are C, and each W is N; or each W, Y, and Z are
C; each R.sup.5 is H, and each R.sup.6 is piperazinyl or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 3; or each R.sup.5 is piperazinyl; and each
R.sup.6 is H.
[0059] In some embodiments, the compound is chosen from:
##STR00053## ##STR00054## ##STR00055## ##STR00056##
or pharmaceutically acceptable salt thereof.
[0060] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0061] The present invention also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0062] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula I:
##STR00057##
wherein:
[0063] X is C(R.sup.7)C(R.sup.8), C(.dbd.O), N(R.sup.9), O, S,
S(.dbd.O), or S(.dbd.O).sub.2;
[0064] R.sup.7, R.sup.8, and R.sup.9 are, independently, H,
C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy, halo, OH, CF.sub.3, or
aromatic group;
[0065] R.sup.1 and R.sup.2 are, independently, H,
C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy, halo, OH,
haloC.sub.1-C.sub.8alkyl, or CN;
[0066] R.sup.3 and R.sup.4 are, independently,
carbocycle(R.sup.5)(R.sup.6);
[0067] each R.sup.5 and each R.sup.6 are, independently, H,
C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy, halo, OH, CF.sub.3,
aromatic group, heterocycle, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8;
or a pharmaceutically acceptable salt thereof.
[0068] In some embodiments, X is N(R.sup.9), O, S, or
S(.dbd.O).sub.2; or X is NH, O, or S; or X is NH or S.
[0069] In any of the above embodiments, R.sup.1 and R.sup.2 are,
independently, H, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy,
halo, OH, haloC.sub.1-C.sub.3alkyl, or CN; or R.sup.1 and R.sup.2
are, independently, H, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy,
halo, or OH; or R.sup.1 and R.sup.2 are, independently, H,
C.sub.1-C.sub.3alkyl, or halo; or R.sup.1 and R.sup.2 are H.
[0070] In any of the above embodiments, R.sup.3 and R.sup.4 are,
independently,
##STR00058##
wherein each W, Y, and Z are, independently, C or N, each A, D, and
Q are, independently, C(R.sup.10)C(R.sup.11), C(.dbd.O),
N(R.sup.12), O, or S, and each R.sup.10, R.sup.11, and R.sup.12
are, independently, H, C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy,
halo, OH, CF.sub.3, or aromatic group.
[0071] In any of the above embodiments, R.sup.3 and R.sup.4 are,
independently,
##STR00059##
wherein each W, Y, and Z are, independently, C or N; or R.sup.3 and
R.sup.4 are, independently,
##STR00060##
wherein each W, Y, and Z are C; or each Y and Z are C and each W is
N.
[0072] In any of the above embodiments, each R.sup.5 is,
independently, H, C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy,
halo, OH, CF.sub.3, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8, and each R.sup.6 is, independently,
heterocycle or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8; or each R.sup.5 is, independently, H,
C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy, halo, OH, or CF.sub.3,
and each R.sup.6 is, independently, heterocycle or the free base or
salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 8; or each R.sup.5 is, independently, H,
C.sub.1-C.sub.3alkyl, halo, or OH, and each R.sup.6 is,
independently, heterocycle or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
4; or each R.sup.5 is, independently, H, C.sub.1-C.sub.3alkyl,
halo, or OH, and each R.sup.6 is, independently, 6-membered
heterocycle or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3; or each R.sup.5 is, independently, H or halo, and each R.sup.6
is piperazinyl or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 where each n is, independently, 1 to
3; or each R.sup.5 is piperazinyl, and each R.sup.6 is,
independently, H, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy,
halo, OH, or CF.sub.3; or each R.sup.5 is piperazinyl, and each
R.sup.6 is H, C.sub.1-C.sub.3alkyl, halo, OH, or CF.sub.3.
[0073] In some embodiments, X is NH, O, S, or S(.dbd.O).sub.2;
R.sup.1 and R.sup.2 are H; R.sup.3 and R.sup.4 are,
independently,
##STR00061##
wherein each W, Y, and Z are, independently, C or N; and each
R.sup.5 and each R.sup.6 are, independently, H, heterocycle, or the
free base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each
n is, independently, 1 to 3.
[0074] In some embodiments, X is NH, O, or S; R.sup.1 and R.sup.2
are H; R.sup.3 and R.sup.4 are
##STR00062##
where each Z and Y are C, and each W is N; or each W, Y, and Z are
C; each R.sup.5 is, independently, H or halo, and each R.sup.6 is
piperazinyl or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3; or each R.sup.5 is piperazinyl, and each R.sup.6 is,
independently, H, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy,
halo, OH, or CF.sub.3.
[0075] In some embodiments, X is NH, O, or S; R.sup.1 and R.sup.2
are H; R.sup.3 and R.sup.4 are
##STR00063##
where each Z and Y are C, and each W is N; or each W, Y, and Z are
C; each R.sup.5 is H, and each R.sup.6 is piperazinyl or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 3; or each R.sup.5 is piperazinyl; and each
R.sup.6 is H.
[0076] In some embodiments, the compound is chosen from:
##STR00064## ##STR00065## ##STR00066## ##STR00067##
##STR00068##
or pharmaceutically acceptable salt thereof.
[0077] In any of the above embodiments, the malaria can be
chloroquine-sensitive or chloroquine-resistant.
[0078] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
I:
##STR00069##
wherein:
[0079] X is C(R.sup.7)C(R.sup.8), C(.dbd.O), N(R.sup.9), O, S,
S(.dbd.O), or S(.dbd.O).sub.2;
[0080] R.sup.7, R.sup.8, and R.sup.9 are, independently, H,
C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy, halo, OH, CF.sub.3, or
aromatic group;
[0081] R.sup.1 and R.sup.2 are, independently, H,
C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy, halo, OH,
haloC.sub.1-C.sub.8alkyl, or CN;
[0082] R.sup.3 and R.sup.4 are, independently,
carbocycle(R.sup.5)(R.sup.6);
[0083] each R.sup.5 and each R.sup.6 are, independently, H,
C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy, halo, OH, CF.sub.3,
aromatic group, heterocycle, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8;
or a pharmaceutically acceptable salt thereof.
[0084] In some embodiments, X is N(R.sup.9), O, S, or
S(.dbd.O).sub.2; or X is NH, O, or S; or X is NH or S.
[0085] In any of the above embodiments, R.sup.1 and R.sup.2 are,
independently, H, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy,
halo, OH, haloC.sub.1-C.sub.3alkyl, or CN; or R.sup.1 and R.sup.2
are, independently, H, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy,
halo, or OH; or R.sup.1 and R.sup.2 are, independently, H,
C.sub.1-C.sub.3alkyl, or halo; or R.sup.1 and R.sup.2 are H.
[0086] In any of the above embodiments, R.sup.3 and R.sup.4 are,
independently,
##STR00070##
wherein each W, Y, and Z are, independently, C or N, each A, D, and
Q are, independently, C(R.sup.10)C(R.sup.11), C(.dbd.O),
N(R.sup.12), O, or S, and each R.sup.10, R.sup.11, and R.sup.12
are, independently, H, C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy,
halo, OH, CF.sub.3, or aromatic group.
[0087] In any of the above embodiments, R.sup.3 and R.sup.4 are,
independently,
##STR00071##
wherein each W, Y, and Z are, independently, C or N; or R.sup.3 and
R.sup.4 are, independently,
##STR00072##
wherein each W, Y, and Z are C; or each Y and Z are C and each W is
N.
[0088] In any of the above embodiments, each R.sup.5 is,
independently, H, C.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxy,
halo, OH, CF.sub.3, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8, and each R.sup.6 is, independently,
heterocycle or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 8; or each R.sup.5 is, independently, H,
C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy, halo, OH, or CF.sub.3,
and each R.sup.6 is, independently, heterocycle or the free base or
salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 8; or each R.sup.5 is, independently, H,
C.sub.1-C.sub.3alkyl, halo, or OH, and each R.sup.6 is,
independently, heterocycle or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
4; or each R.sup.5 is, independently, H, C.sub.1-C.sub.3alkyl,
halo, or OH, and each R.sup.6 is, independently, 6-membered
heterocycle or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3; or each R.sup.5 is, independently, H or halo, and each R.sup.6
is piperazinyl or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 where each n is, independently, 1 to
3; or each R.sup.5 is piperazinyl, and each R.sup.6 is,
independently, H, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy,
halo, OH, or CF.sub.3; or each R.sup.5 is piperazinyl, and each
R.sup.6 is H, C.sub.1-C.sub.3alkyl, halo, OH, or CF.sub.3.
[0089] In some embodiments, X is NH, O, S, or S(.dbd.O).sub.2;
R.sup.1 and R.sup.2 are H; R.sup.3 and R.sup.4 are,
independently,
##STR00073##
wherein each W, Y, and Z are, independently, C or N; and each
R.sup.5 and each R.sup.6 are, independently, H, heterocycle, or the
free base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each
n is, independently, 1 to 3.
[0090] In some embodiments, X is NH, O, or S; R.sup.1 and R.sup.2
are H; R.sup.3 and R.sup.4 are
##STR00074##
where each Z and Y are C, and each W is N; or each W, Y, and Z are
C; each R.sup.5 is, independently, H or halo, and each R.sup.6 is
piperazinyl or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
3; or each R.sup.5 is piperazinyl, and each R.sup.6 is,
independently, H, C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3alkoxy,
halo, OH, or CF.sub.3.
[0091] In some embodiments, X is NH, O, or S; R.sup.1 and R.sup.2
are H; R.sup.3 and R.sup.4 are
##STR00075##
where each Z and Y are C, and each W is N; or each W, Y, and Z are
C; each R.sup.5 is H, and each R.sup.6 is piperazinyl or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 3; or each R.sup.5 is piperazinyl; and each
R.sup.6 is H.
[0092] In some embodiments, the compound is chosen from:
##STR00076## ##STR00077## ##STR00078## ##STR00079##
or pharmaceutically acceptable salt thereof.
[0093] The present invention also provides compounds of Formula
II:
##STR00080##
wherein:
[0094] X is O or S;
[0095] each Y is, independently, O, S, or N;
[0096] each R.sup.1 is, independently, H, 5- or 6-membered
heterocycle, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each R.sup.1 is, independently, together
with Y a 5- or 6-membered heterocycle;
[0097] each R.sup.2 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH; and
[0098] each R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0099] In some embodiments, X is O.
[0100] In any of the above embodiments, each Y is O or S.
[0101] In any of the above embodiments, each R.sup.1 is,
independently, 5-membered heterocycle or the free base or salt form
of --(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1
to 4; or each R.sup.1 is, independently, 3-pyrrolyl or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2.
[0102] In any of the above embodiments, each R.sup.2 is,
independently, CF.sub.3, C(CH.sub.3).sub.3, or halo.
[0103] In any of the above embodiments, each R.sup.3 is,
independently, (CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each
n is, independently, 1 to 4; or each R.sup.3 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0104] In some embodiments, X is O or S; each Y is, independently,
O or S; each R.sup.1 is, independently, 5-membered heterocycle, or
the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where
each n is, independently, 1 to 4; each R.sup.2 is, independently,
CF.sub.3 or C(CH.sub.3).sub.3; and each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0105] In some embodiments, X is O or S; each Y is O or S; each
R.sup.1 is 5-membered heterocycle, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 to 4; each R.sup.2
is CF.sub.3 or C(CH.sub.3).sub.3; and each R.sup.3 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 to
4.
[0106] In some embodiments, X is O or S; each Y is O or S; each
R.sup.1 is 3-pyrrolyl, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2; each R.sup.2 is
CF.sub.3 or C(CH.sub.3).sub.3; and each R.sup.3 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0107] In some embodiments, the compound is chosen from:
##STR00081##
or a pharmaceutically acceptable salt thereof.
[0108] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0109] The present invention also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0110] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula II:
##STR00082##
wherein:
[0111] X is O or S;
[0112] each Y is, independently, O, S, or N;
[0113] each R.sup.1 is, independently, H, 5- or 6-membered
heterocycle, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each R.sup.1 is, independently, together
with Y a 5- or 6-membered heterocycle;
[0114] each R.sup.2 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH; and
[0115] each R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0116] In some embodiments, X is O.
[0117] In any of the above embodiments, each Y is O or S.
[0118] In any of the above embodiments, each R.sup.1 is,
independently, 5-membered heterocycle or the free base or salt form
of --(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1
to 4; or each R.sup.1 is, independently, 3-pyrrolyl or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2.
[0119] In any of the above embodiments, each R.sup.2 is,
independently, CF.sub.3, C(CH.sub.3).sub.3, or halo.
[0120] In any of the above embodiments, each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is, independently, 1 to 4; or each R.sup.3 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0121] In some embodiments, X is O or S; each Y is, independently,
O or S; each R.sup.1 is, independently, 5-membered heterocycle, or
the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where
each n is, independently, 1 to 4; each R.sup.2 is, independently,
CF.sub.3 or C(CH.sub.3).sub.3; and each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0122] In some embodiments, X is O or S; each Y is O or S; each
R.sup.1 is 5-membered heterocycle, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 to 4; each R.sup.2
is CF.sub.3 or C(CH.sub.3).sub.3; and each R.sup.3 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 to
4.
[0123] In some embodiments, X is O or S; each Y is O or S; each
R.sup.1 is 3-pyrrolyl, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2; each R.sup.2 is
CF.sub.3 or C(CH.sub.3).sub.3; and each R.sup.3 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0124] In some embodiments, the compound is chosen from:
##STR00083##
or a pharmaceutically acceptable salt thereof.
[0125] In any of the above embodiments, the malaria can be
chloroquine-sensitive or chloroquine-resistant.
[0126] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
II:
##STR00084##
wherein:
[0127] X is O or S;
[0128] each Y is, independently, O, S, or N;
[0129] each R.sup.1 is, independently, H, 5- or 6-membered
heterocycle, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each R.sup.1 is, independently, together
with Y a 5- or 6-membered heterocycle;
[0130] each R.sup.2 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH; and
[0131] each R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0132] In some embodiments, X is O.
[0133] In any of the above embodiments, each Y is O or S.
[0134] In any of the above embodiments, each R.sup.1 is,
independently, 5-membered heterocycle or the free base or salt form
of --(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1
to 4; or each R.sup.1 is, independently, 3-pyrrolyl or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2.
[0135] In any of the above embodiments, each R.sup.2 is,
independently, CF.sub.3, C(CH.sub.3).sub.3, or halo. In any of the
above embodiments, each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each R.sup.3 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0136] In some embodiments, X is O or S; each Y is, independently,
O or S; each R.sup.1 is, independently, 5-membered heterocycle, or
the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where
each n is, independently, 1 to 4; each R.sup.2 is, independently,
CF.sub.3 or C(CH.sub.3).sub.3; and each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0137] In some embodiments, X is O or S; each Y is O or S; each
R.sup.1 is 5-membered heterocycle, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 to 4; each R.sup.2
is CF.sub.3 or C(CH.sub.3).sub.3; and each R.sup.3 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 to
4.
[0138] In some embodiments, X is O or S; each Y is O or S; each
R.sup.1 is 3-pyrrolyl, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2; each R.sup.2 is
CF.sub.3 or C(CH.sub.3).sub.3; and each R.sup.3 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0139] In some embodiments, the compound is chosen from:
##STR00085##
or a pharmaceutically acceptable salt thereof.
[0140] The present invention also provides compounds of Formula
III:
Q-X--Z--X-Q
wherein:
[0141] Z is
##STR00086##
or phenyl;
[0142] each Q is, independently,
##STR00087##
or --C(.dbd.O)--(CH.sub.2).sub.b--NH--C(.dbd.NH)--NH.sub.2, where
each b is, independently, 1 to 4;
[0143] each X is, independently, O, S, or N;
[0144] each R.sup.1 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH;
[0145] each R.sup.3 is, independently, H, --NH--R.sup.2,
--(CH.sub.2).sub.r--NH.sub.2, --NH.sub.2,
--NH--(CH.sub.2).sub.w--NH.sub.2, or
##STR00088##
where each r is, independently, 1 or 2, each w is, independently, 1
to 3, and each y is, independently, 1 or 2;
[0146] each R.sup.2 is, independently, H, or the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
[0147] each R.sup.4 is, independently, H,
--NH--C(.dbd.O)--(CH.sub.2).sub.p--NH--C(.dbd.NH)--NH.sub.2 or
##STR00089##
where each p is, independently, 1 to 6, and each q is,
independently, 1 or 2; and
[0148] each R.sup.5 is, independently, H or CF.sub.3;
or a pharmaceutically acceptable salt thereof.
[0149] In some embodiments, Z is
##STR00090##
[0150] In any of the above embodiments, each Q is,
independently,
##STR00091##
[0151] In any of the above embodiments, each X is O.
[0152] In any of the above embodiments, each R.sup.1 is,
independently, H, CF.sub.3, or halo; or each R.sup.1 is
CF.sub.3.
[0153] In any of the above embodiments, each R.sup.3 is,
independently, --NH--R.sup.2.
[0154] In any of the above embodiments, each R.sup.2 is,
independently, H, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
4; or each R.sup.2 is, independently, the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2; or each R.sup.2 is the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2.
[0155] In any of the above embodiments, each R.sup.4 and each
R.sup.5 is H.
[0156] In some embodiments, Z is
##STR00092##
each Q is, independently,
##STR00093##
each X is O or S; each R.sup.1 is, independently, CF.sub.3,
C(CH.sub.3).sub.3, or halo; each R.sup.3 is, independently,
--NH--R.sup.2; each R.sup.2 is, independently, H, or the free base
or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 4; and each R.sup.4 and each R.sup.5 is H.
[0157] In some embodiments, Z is
##STR00094##
each Q is, independently,
##STR00095##
each X is O; each R.sup.1 is CF.sub.3, C(CH.sub.3).sub.3, or halo;
each R.sup.3 is, independently, --NH--R.sup.2; each R.sup.2 is,
independently, the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2; and each
R.sup.4 and each R.sup.5 is H.
[0158] In some embodiments, Z is
##STR00096##
each Q is, independently,
##STR00097##
each X is O; each R.sup.1 is CF.sub.3 or halo; each R.sup.3 is,
independently, --NH--R.sup.2; each R.sup.2 is the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2, where each n is 2; and each
R.sup.4 and each R.sup.5 is H.
[0159] In some embodiments, Z is
##STR00098##
each Q is, independently,
##STR00099##
each X is, independently, O, or S; each R.sup.1 is, independently,
H, or CF.sub.3; each R.sup.3 is H; each R.sup.4 is, independently,
H or --NH--C(.dbd.O)--(CH.sub.2).sub.p--NH--C(.dbd.NH)--NH.sub.2,
where each p is, independently, 3 or 4; and each R.sup.5 is,
independently, H or CF.sub.3.
[0160] In some embodiments, Z is
##STR00100##
each Q is, independently,
--C(.dbd.O)--(CH.sub.2).sub.b--NH--C(.dbd.NH)--NH.sub.2, where each
b is, independently, 3 or 4; and each X is N.
[0161] In some embodiments, Z is
##STR00101##
each Q is, independently,
##STR00102##
[0162] each X is O or S; each R.sup.1 is, independently, H or
CF.sub.3; each R.sup.3 is, independently,
--(CH.sub.2).sub.r--NH.sub.2, --NH.sub.2,
--NH--(CH.sub.2).sub.w--NH.sub.2, or
##STR00103##
where each r is, independently, 1 or 2, each w is, independently, 1
to 3, and each y is, independently, 1 or 2; each R.sup.4 is H; and
each R.sup.5 is, independently, H or CF.sub.3.
[0163] In some embodiments, Z is
##STR00104##
or phenyl; each Q is, independently,
##STR00105##
[0164] each X is, independently, O or S; each R.sup.1 is,
independently, H or CF.sub.3; each R.sup.3 is H; each R.sup.4 is,
independently,
##STR00106##
where each q is, independently, 1 or 2; and each R.sup.5 is,
independently, H or CF.sub.3.
[0165] In some embodiments, the compound is chosen from:
##STR00107## ##STR00108##
or a pharmaceutically acceptable salt thereof.
[0166] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0167] The present invention also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0168] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula III:
Q-X--Z--X-Q
wherein:
[0169] Z is
##STR00109##
or phenyl;
[0170] each Q is, independently,
##STR00110##
or --C(.dbd.O)--(CH.sub.2).sub.b--NH--C(.dbd.NH)--NH.sub.2, where
each b is, independently, 1 to 4;
[0171] each X is, independently, O, S, or N;
[0172] each R.sup.1 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH;
[0173] each R.sup.3 is, independently, H, --NH--R.sup.2,
--(CH.sub.2).sub.r--NH.sub.2, --NH.sub.2,
--NH--(CH.sub.2).sub.w--NH.sub.2, or
##STR00111##
where each r is, independently, 1 or 2, each w is, independently, 1
to 3, and each y is, independently, 1 or 2;
[0174] each R.sup.2 is, independently, H, or the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
[0175] each R.sup.4 is, independently, H,
--NH--C(.dbd.O)--(CH.sub.2).sub.p--NH--C(.dbd.NH)--NH.sub.2 or
##STR00112##
where each p is, independently, 1 to 6, and each q is,
independently, 1 or 2; and
[0176] each R.sup.5 is, independently, H or CF.sub.3;
or a pharmaceutically acceptable salt thereof.
[0177] In some embodiments, Z is
##STR00113##
[0178] In any of the above embodiments, each Q is,
independently,
##STR00114##
[0179] In any of the above embodiments, each X is O.
[0180] In any of the above embodiments, each R.sup.1 is,
independently, H, CF.sub.3, or halo; or each R.sup.1 is
CF.sub.3.
[0181] In any of the above embodiments, each R.sup.3 is,
independently, --NH--R.sup.2. In any of the above embodiments, each
R.sup.2 is, independently, H, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
4; or each R.sup.2 is, independently, the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2; or each R.sup.2 is the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2.
[0182] In any of the above embodiments, each R.sup.4 and each
R.sup.5 is H.
[0183] In some embodiments, Z is
##STR00115##
each Q is, independently,
##STR00116##
[0184] each X is O or S; each R.sup.1 is, independently, CF.sub.3,
C(CH.sub.3).sub.3, or halo; each R.sup.3 is, independently,
--NH--R.sup.2; each R.sup.2 is, independently, H, or the free base
or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 4; and each R.sup.4 and each R.sup.5 is H.
[0185] In some embodiments, Z is
##STR00117##
each Q is, independently,
##STR00118##
each X is O; each R.sup.1 is CF.sub.3, C(CH.sub.3).sub.3, or halo;
each R.sup.3 is, independently, --NH--R.sup.2; each R.sup.2 is,
independently, the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2; and each
R.sup.4 and each R.sup.5 is H.
[0186] In some embodiments, Z is
##STR00119##
each Q is, independently,
##STR00120##
each X is O; each R.sup.1 is CF.sub.3 or halo; each R.sup.3 is,
independently, --NH--R.sup.2; each R.sup.2 is the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2, where each n is 2; and each
R.sup.4 and each R.sup.5 is H.
[0187] In some embodiments, Z is
##STR00121##
each Q is, independently,
##STR00122##
each X is, independently, O, or S; each R.sup.1 is, independently,
H, or CF.sub.3; each R.sup.3 is H; each R.sup.4 is, independently,
H or --NH--C(.dbd.O)--(CH.sub.2).sub.p--NH--C(.dbd.NH)--NH.sub.2,
where each p is, independently, 3 or 4; and each R.sup.5 is,
independently, H or CF.sub.3.
[0188] In some embodiments, Z is
##STR00123##
each Q is, independently,
--C(.dbd.O)--(CH.sub.2).sub.b--NH--C(.dbd.NH)--NH.sub.2, where each
b is, independently, 3 or 4; and each X is N.
[0189] In some embodiments, Z is
##STR00124##
each Q is, independently,
##STR00125##
each X is O or S; each R.sup.1 is, independently, H or CF.sub.3;
each R.sup.3 is, independently, --(CH.sub.2).sub.r--NH.sub.2,
--NH.sub.2, --NH--(CH.sub.2).sub.w--NH.sub.2, or
##STR00126##
where each r is, independently, 1 or 2, each w is, independently, 1
to 3, and each y is, independently, 1 or 2; each R.sup.4 is H; and
each R.sup.5 is, independently, H or CF.sub.3.
[0190] In some embodiments, Z is
##STR00127##
or phenyl; each Q is, independently,
##STR00128##
each X is, independently, O or S; each R.sup.1 is, independently, H
or CF.sub.3; each R.sup.3 is H; each R.sup.4 is, independently,
##STR00129##
where each q is, independently, 1 or 2; and each R.sup.5 is,
independently, H or CF.sub.3.
[0191] In some embodiments, the compound is chosen from:
##STR00130## ##STR00131##
or a pharmaceutically acceptable salt thereof.
[0192] In any of the above embodiments, the malaria can be
chloroquine-sensitive or chloroquine-resistant.
[0193] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
III:
Q-X--Z--X-Q
wherein:
[0194] Z is
##STR00132##
or phenyl;
[0195] each Q is, independently,
##STR00133##
or --C(.dbd.O)--(CH.sub.2).sub.b--NH--C(.dbd.NH)--NH.sub.2, where
each b is, independently, 1 to 4;
[0196] each X is, independently, O, S, or N;
[0197] each R.sup.1 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH;
[0198] each R.sup.3 is, independently, H, --NH--R.sup.2,
--(CH.sub.2).sub.r--NH.sub.2, --NH.sub.2,
--NH--(CH.sub.2).sub.w--NH.sub.2, or
##STR00134##
where each r is, independently, 1 or 2, each w is, independently, 1
to 3, and each y is, independently, 1 or 2;
[0199] each R.sup.2 is, independently, H, or the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
[0200] each R.sup.4 is, independently, H,
--NH--C(.dbd.O)--(CH.sub.2).sub.p--NH--C(.dbd.NH)--NH.sub.2 or
##STR00135##
where each p is, independently, 1 to 6, and each q is,
independently, 1 or 2; and
[0201] each R.sup.5 is, independently, H or CF.sub.3;
or a pharmaceutically acceptable salt thereof.
[0202] In some embodiments, Z is
##STR00136##
[0203] In any of the above embodiments, each Q is,
independently,
##STR00137##
[0204] In any of the above embodiments, each X is O.
[0205] In any of the above embodiments, each R.sup.1 is,
independently, H, CF.sub.3, or halo; or each R.sup.1 is
CF.sub.3.
[0206] In any of the above embodiments, each R.sup.3 is,
independently, --NH--R.sup.2.
[0207] In any of the above embodiments, each R.sup.2 is,
independently, H, or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
4; or each R.sup.2 is, independently, the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2; or each R.sup.2 is the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2.
[0208] In any of the above embodiments, each R.sup.4 and each
R.sup.5 is H.
[0209] In some embodiments, Z is
##STR00138##
[0210] each Q is, independently,
##STR00139##
each X is O or S; each R.sup.1 is, independently, CF.sub.3,
C(CH.sub.3).sub.3, or halo; each R.sup.3 is, independently,
--NH--R.sup.2; each R.sup.2 is, independently, H, or the free base
or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 4; and each R.sup.4 and each R.sup.5 is H.
[0211] In some embodiments, Z is
##STR00140##
each Q is, independently,
##STR00141##
each X is O; each R.sup.1 is CF.sub.3, C(CH.sub.3).sub.3, or halo;
each R.sup.3 is, independently, --NH--R.sup.2; each R.sup.2 is,
independently, the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2; and each
R.sup.4 and each R.sup.5 is H.
[0212] In some embodiments, Z is
##STR00142##
each Q is, independently,
##STR00143##
each X is O; each R.sup.1 is CF.sub.3 or halo; each R.sup.3 is,
independently, --NH--R.sup.2; each R.sup.2 is the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2, where each n is 2; and each
R.sup.4 and each R.sup.5 is H.
[0213] In some embodiments, Z is
##STR00144##
each Q is, independently,
##STR00145##
each X is, independently, O, or S; each R.sup.1 is, independently,
H, or CF.sub.3; each R.sup.3 is H; each R.sup.4 is, independently,
H or --NH--C(.dbd.O)--(CH.sub.2).sub.p--NH--C(.dbd.NH)--NH.sub.2,
where each p is, independently, 3 or 4; and each R.sup.5 is,
independently, H or CF.sub.3.
[0214] In some embodiments, Z is
##STR00146##
each Q is, independently,
--C(.dbd.O)--(CH.sub.2).sub.b--NH--C(.dbd.NH)--NH.sub.2, where each
b is, independently, 3 or 4; and each X is N.
[0215] In some embodiments, Z is
##STR00147##
each Q is, independently,
##STR00148##
each X is O or S; each R.sup.1 is, independently, H or CF.sub.3;
each R.sup.3 is, independently, --(CH.sub.2).sub.r--NH.sub.2,
--NH.sub.2, --NH--(CH.sub.2).sub.w--NH.sub.2, or
##STR00149##
where each r is, independently, 1 or 2, each w is, independently, 1
to 3, and each y is, independently, 1 or 2; each R.sup.4 is H; and
each R.sup.5 is, independently, H or CF.sub.3.
[0216] In some embodiments, Z is
##STR00150##
or phenyl; each Q is, independently,
##STR00151##
each X is, independently, O or S; each R.sup.1 is, independently, H
or CF.sub.3; each R.sup.3 is H; each R.sup.4 is, independently,
##STR00152##
where each q is, independently, 1 or 2; and each R.sup.5 is,
independently, H or CF.sub.3.
[0217] In some embodiments, the compound is chosen from:
##STR00153## ##STR00154##
or a pharmaceutically acceptable salt thereof.
[0218] The present invention also provides compounds of Formula
IV:
##STR00155##
wherein:
[0219] G is
##STR00156##
[0220] each X is, independently, O or S;
[0221] each R.sup.1 is, independently,
##STR00157##
or the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
[0222] each R.sup.2 is, independently, H, C.sub.1-C.sub.8alkyl, or
the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
[0223] each R.sup.3 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH; and
[0224] each R.sup.4 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0225] In some embodiments, G is
##STR00158##
and each X is S.
[0226] In any of the above embodiments, each R.sup.1 is,
independently, the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
4; or each R.sup.1 is, independently, the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2; or each R.sup.1 is the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2.
[0227] In any of the above embodiments, each R.sup.2 is,
independently, C.sub.1-C.sub.3alkyl or the free base or salt form
of --(CH.sub.2).sub.n--NH.sub.2 where n is 1 to 4; or each R.sup.2
is, independently, C.sub.1-C.sub.3alkyl or the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2; or each R.sup.2 is, independently, methyl or
the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where
each n is, independently, 2; or each R.sup.2 is methyl or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is
2.
[0228] In any of the above embodiments, each R.sup.3 is,
independently, CF.sub.3, C(CH.sub.3).sub.3, or halo; or each
R.sup.3 is CF.sub.3.
[0229] In any of the above embodiments, each R.sup.4 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is, independently, 1 to 4; or each R.sup.4 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0230] In some embodiments, G is
##STR00159##
each X is S; each R.sup.1 is, independently, the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2; each R.sup.2 is, independently,
C.sub.1-C.sub.8alkyl or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2; each R.sup.3 is, independently, CF.sub.3, C(CH.sub.3).sub.3, or
halo; and each R.sup.4 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 3 or 4.
[0231] In some embodiments, G is
##STR00160##
each X is S; each R.sup.1 is the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2; each R.sup.2
is, independently, C.sub.1-C.sub.3alkyl or the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2, where each n is 2; each
R.sup.3 is, independently, CF.sub.3 or C(CH.sub.3).sub.3; and each
R.sup.4 is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n
is 3 or 4.
[0232] In some embodiments, G is
##STR00161##
each X is S; each R.sup.1 is the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2; each R.sup.2 is,
independently, methyl or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2; each R.sup.3 is,
independently, CF.sub.3 or C(CH.sub.3).sub.3; and each R.sup.4 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0233] In some embodiments, G is
##STR00162##
each X is, independently, O or S; each R.sup.1 is, independently,
the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.3 is, independently, H or
CF.sub.3; and each R.sup.4 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0234] In some embodiments, G is
##STR00163##
each X is, independently, O or S; each R.sup.1 is
##STR00164##
each R.sup.3 is, independently, H or CF.sub.3; and each R.sup.4 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0235] In some embodiments, the compound is chosen from:
##STR00165##
or a pharmaceutically acceptable salt thereof.
[0236] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0237] The present invention also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0238] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula IV:
##STR00166##
wherein:
[0239] G is
##STR00167##
[0240] each X is, independently, O or S;
[0241] each R.sup.1 is, independently,
##STR00168##
or the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
[0242] each R.sup.2 is, independently, H, C.sub.1-C.sub.8alkyl, or
the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
[0243] each R.sup.3 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH; and
[0244] each R.sup.4 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0245] In some embodiments, G is
##STR00169##
and each X is S.
[0246] In any of the above embodiments, each R.sup.1 is,
independently, the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
4; or each R.sup.1 is, independently, the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2; or each R.sup.1 is the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2.
[0247] In any of the above embodiments, each R.sup.2 is,
independently, C.sub.1-C.sub.3alkyl or the free base or salt form
of --(CH.sub.2).sub.n--NH.sub.2 where n is 1 to 4; or each R.sup.2
is, independently, C.sub.1-C.sub.3alkyl or the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2; or each R.sup.2 is, independently, methyl or
the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where
each n is, independently, 2; or each R.sup.2 is methyl or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is
2.
[0248] In any of the above embodiments, each R.sup.3 is,
independently, CF.sub.3, C(CH.sub.3).sub.3, or halo; or each
R.sup.3 is CF.sub.3.
[0249] In any of the above embodiments, each R.sup.4 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is, independently, 1 to 4; or each R.sup.4 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0250] In some embodiments, G is
##STR00170##
each X is S; each R.sup.1 is, independently, the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2; each R.sup.2 is, independently,
C.sub.1-C.sub.8alkyl or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2; each R.sup.3 is, independently, CF.sub.3, C(CH.sub.3).sub.3, or
halo; and each R.sup.4 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 3 or 4.
[0251] In some embodiments, G is
##STR00171##
each X is S; each R.sup.1 is the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2; each R.sup.2
is, independently, C.sub.1-C.sub.3alkyl or the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2, where each n is 2; each
R.sup.3 is, independently, CF.sub.3 or C(CH.sub.3).sub.3; and each
R.sup.4 is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n
is 3 or 4.
[0252] In some embodiments, G is
##STR00172##
each X is S; each R.sup.1 is the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2; each R.sup.2 is,
independently, methyl or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2; each R.sup.3 is,
independently, CF.sub.3 or C(CH.sub.3).sub.3; and each R.sup.4 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0253] In some embodiments, G is
##STR00173##
each X is, independently, O or S; each R.sup.1 is, independently,
the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.3 is, independently, H or
CF.sub.3; and each R.sup.4 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0254] In some embodiments, G is
##STR00174##
each X is, independently, O or S; each R.sup.1 is
##STR00175##
each R.sup.3 is, independently, H or CF.sub.3; and each R.sup.4 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0255] In some embodiments, the compound is chosen from:
##STR00176##
or a pharmaceutically acceptable salt thereof.
[0256] In any of the above embodiments, the malaria can be
chloroquine-sensitive or chloroquine-resistant.
[0257] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
IV:
##STR00177##
wherein:
[0258] G is
##STR00178##
[0259] each X is, independently, O or S;
[0260] each R.sup.1 is, independently,
##STR00179##
or the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
[0261] each R.sup.2 is, independently, H, C.sub.1-C.sub.8alkyl, or
the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
[0262] each R.sup.3 is, independently, H, CF.sub.3,
C(CH.sub.3).sub.3, halo, or OH; and
[0263] each R.sup.4 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0264] In some embodiments, G is
##STR00180##
and each X is S.
[0265] In any of the above embodiments, each R.sup.1 is,
independently, the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 to
4; or each R.sup.1 is, independently, the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2; or each R.sup.1 is the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2.
[0266] In any of the above embodiments, each R.sup.2 is,
independently, C.sub.1-C.sub.3alkyl or the free base or salt form
of --(CH.sub.2).sub.n--NH.sub.2 where n is 1 to 4; or each R.sup.2
is, independently, C.sub.1-C.sub.3alkyl or the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2; or each R.sup.2 is, independently, methyl or
the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where
each n is, independently, 2; or each R.sup.2 is methyl or the free
base or salt form of --(CH.sub.2).sub.n--NH.sub.2, where each n is
2.
[0267] In any of the above embodiments, each R.sup.3 is,
independently, CF.sub.3, C(CH.sub.3).sub.3, or halo; or each
R.sup.3 is CF.sub.3.
[0268] In any of the above embodiments, each R.sup.4 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is, independently, 1 to 4; or each R.sup.4 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0269] In some embodiments, G is
##STR00181##
each X is S; each R.sup.1 is, independently, the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2; each R.sup.2 is, independently,
C.sub.1-C.sub.8alkyl or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2; each R.sup.3 is, independently, CF.sub.3, C(CH.sub.3).sub.3, or
halo; and each R.sup.4 is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 3 or 4.
[0270] In some embodiments, G is
##STR00182##
each X is S; each R.sup.1 is the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2; each R.sup.2
is, independently, C.sub.1-C.sub.3alkyl or the free base or salt
form of --(CH.sub.2).sub.n--NH.sub.2, where each n is 2; each
R.sup.3 is, independently, CF.sub.3 or C(CH.sub.3).sub.3; and each
R.sup.4 is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n
is 3 or 4.
[0271] In some embodiments, G is
##STR00183##
each X is S; each R.sup.1 is the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2; each R.sup.2 is,
independently, methyl or the free base or salt form of
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2; each R.sup.3 is,
independently, CF.sub.3 or C(CH.sub.3).sub.3; and each R.sup.4 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0272] In some embodiments, G is
##STR00184##
each X is, independently, O or S; each R.sup.1 is, independently,
the free base or salt form of --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.3 is, independently, H or
CF.sub.3; and each R.sup.4 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0273] In some embodiments, G is
##STR00185##
each X is, independently, O or S; each R.sup.1 is
##STR00186##
each R.sup.3 is, independently, H or CF.sub.3; and each R.sup.4 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0274] In some embodiments, the compound is chosen from:
##STR00187##
or a pharmaceutically acceptable salt thereof.
[0275] The present invention also provides compounds of Formula
V:
##STR00188##
wherein:
[0276] each X is, independently, O, S, or S(.dbd.O).sub.2;
[0277] each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H,
C.sub.1-C.sub.3alkyl, or --(CH.sub.2).sub.p--NH.sub.2, where each p
is, independently, 1 or 2;
[0278] each R.sup.2 is, independently, H, halo, CF.sub.3, or
C(CH.sub.3).sub.3; and
[0279] each V.sup.2 is H, and each V.sup.1 is, independently,
--N--C(.dbd.O)--R.sup.3, where each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof;
[0280] provided that the compound is not:
##STR00189##
[0281] In some embodiments, each X is S.
[0282] In any of the above embodiments, each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 or 2, and each R.sup.4 is, independently, H or
methyl; or each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is 2 and
each R.sup.4 is H; or each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each R.sup.1 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2.
[0283] In any of the above embodiments, each R.sup.2 is,
independently, H, Br, F, Cl, CF.sub.3, or C(CH.sub.3).sub.3; or
each R.sup.2 is Br, F, Cl, CF.sub.3, or C(CH.sub.3).sub.3.
[0284] In any of the above embodiments, each V.sup.2 is H and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.2 is H and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 or 2; or each V.sup.2 is H and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.2 is H and each V.sup.1 is --N--C(.dbd.O)--R.sup.3,
where each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is 2.
[0285] In any of the above embodiments, each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
or each V.sup.1 is H and each V.sup.2 is, independently,
--S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.1 is H and each V.sup.2 is --S--R.sup.5, where each
R.sup.5 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2.
[0286] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 4.
[0287] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2; each R.sup.2 is, independently, CF.sub.3 or
C(CH.sub.3).sub.3; and each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2.
[0288] In some embodiments, each X is S; each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2; each R.sup.2
is, independently, CF.sub.3 or C(CH.sub.3).sub.3; and each V.sup.1
is H and each V.sup.2 is --S--R.sup.5, where each R.sup.5 is
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2.
[0289] In some embodiments, each X is O or S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H or
methyl; each R.sup.2 is, independently, halo, CF.sub.3, or
C(CH.sub.3).sub.3; and each V.sup.2 is H, and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0290] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where
each n is, independently, 1 or 2, and each R.sup.4 is,
independently, H or methyl; each R.sup.2 is, independently, halo;
and each V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3,
where each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0291] In some embodiments, each X is O or S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.2 is H, and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0292] In some embodiments, each X is O or S; each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
each R.sup.2 is halo, CF.sub.3, or C(CH.sub.3).sub.3; and each
V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3, where
each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 3 or
4.
[0293] In some embodiments, each X is, independently, S or
S(.dbd.O).sub.2; each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.p--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 or 2, and each R.sup.4 is, independently,
--(CH.sub.2).sub.p--NH.sub.2, where each p is, independently, 1 or
2; each R.sup.2 is, independently, halo or CF.sub.3; and each
V.sup.2 is H, and each V.sup.1 is, independently,
--N--C(.dbd.O)--R.sup.3, where each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 3 or 4.
[0294] In some embodiments, the compound is chosen from:
##STR00190## ##STR00191## ##STR00192##
or a pharmaceutically acceptable salt thereof.
[0295] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0296] The present invention also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0297] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula V:
##STR00193##
wherein:
[0298] each X is, independently, O, S, or S(.dbd.O).sub.2;
[0299] each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H,
C.sub.1-C.sub.3alkyl, or --(CH.sub.2).sub.p--NH.sub.2, where each p
is, independently, 1 or 2;
[0300] each R.sup.2 is, independently, H, halo, CF.sub.3, or
C(CH.sub.3).sub.3; and
[0301] each V.sup.2 is H, and each V.sup.1 is, independently,
--N--C(.dbd.O)--R.sup.3, where each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0302] In some embodiments, each X is S.
[0303] In any of the above embodiments, each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 or 2, and each R.sup.4 is, independently, H or
methyl; or each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is 2 and
each R.sup.4 is H; or each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each R.sup.1 is --(CH.sub.2).sub.n--NH.sub.2 or, where each n is
2.
[0304] In any of the above embodiments, each R.sup.2 is,
independently, H, Br, F, Cl, CF.sub.3, or C(CH.sub.3).sub.3; or
each R.sup.2 is Br, F, Cl, CF.sub.3, or C(CH.sub.3).sub.3.
[0305] In any of the above embodiments, each V.sup.2 is H and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.2 is H and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 or 2; or each V.sup.2 is H and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.2 is H and each V.sup.1 is --N--C(.dbd.O)--R.sup.3,
where each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is 2.
[0306] In any of the above embodiments, each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
or each V.sup.1 is H and each V.sup.2 is, independently,
--S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.1 is H and each V.sup.2 is --S--R.sup.5, where each
R.sup.5 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2.
[0307] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 4.
[0308] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2; each R.sup.2 is, independently, CF.sub.3 or
C(CH.sub.3).sub.3; and each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2.
[0309] In some embodiments, each X is S; each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2; each R.sup.2
is, independently, CF.sub.3 or C(CH.sub.3).sub.3; and each V.sup.1
is H and each V.sup.2 is --S--R.sup.5, where each R.sup.5 is
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2.
[0310] In some embodiments, each X is O or S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.p--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H or
methyl; each R.sup.2 is, independently, halo, CF.sub.3, or
C(CH.sub.3).sub.3; and each V.sup.2 is H, and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0311] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.p--NH--C(.dbd.O)--R.sup.4, where
each n is, independently, 1 or 2, and each R.sup.4 is,
independently, H or methyl; each R.sup.2 is, independently, halo;
and each V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3,
where each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0312] In some embodiments, each X is O or S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.2 is H, and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0313] In some embodiments, each X is O or S; each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
each R.sup.2 is halo, CF.sub.3, or C(CH.sub.3).sub.3; and each
V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3, where
each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 3 or
4.
[0314] In some embodiments, each X is, independently, S or
S(.dbd.O).sub.2; each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.p--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 or 2, and each R.sup.4 is, independently,
--(CH.sub.2).sub.p--NH.sub.2, where each p is, independently, 1 or
2; each R.sup.2 is, independently, halo or CF.sub.3; and each
V.sup.2 is H, and each V.sup.1 is, independently,
--N--C(.dbd.O)--R.sup.3, where each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 3 or 4.
[0315] In some embodiments, the compound is chosen from:
##STR00194## ##STR00195## ##STR00196## ##STR00197##
or a pharmaceutically acceptable salt thereof.
[0316] In any of the above embodiments, the malaria can be
chloroquine-sensitive or chloroquine-resistant.
[0317] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
V:
##STR00198##
wherein:
[0318] each X is, independently, O, S, or S(.dbd.O).sub.2;
[0319] each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H,
C.sub.1-C.sub.3alkyl, or --(CH.sub.2).sub.p--NH.sub.2, where each p
is, independently, 1 or 2;
[0320] each R.sup.2 is, independently, H, halo, CF.sub.3, or
C(CH.sub.3).sub.3; and
[0321] each V.sup.2 is H, and each V.sup.1 is, independently,
--N--C(.dbd.O)--R.sup.3, where each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0322] In some embodiments, each X is S.
[0323] In any of the above embodiments, each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 or 2, and each R.sup.4 is, independently, H or
methyl; or each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is 2 and
each R.sup.4 is H; or each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each R.sup.1 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2.
[0324] In any of the above embodiments, each R.sup.2 is,
independently, H, Br, F, Cl, CF.sub.3, or C(CH.sub.3).sub.3; or
each R.sup.2 is Br, F, Cl, CF.sub.3, or C(CH.sub.3).sub.3.
[0325] In any of the above embodiments, each V.sup.2 is H and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.2 is H and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 or 2; or each V.sup.2 is H and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.2 is H and each V.sup.1 is --N--C(.dbd.O)--R.sup.3,
where each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where n is 2.
[0326] In any of the above embodiments, each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; or each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
or each V.sup.1 is H and each V.sup.2 is, independently,
--S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2; or
each V.sup.1 is H and each V.sup.2 is --S--R.sup.5, where each
R.sup.5 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 2.
[0327] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.1 is H and each
V.sup.2 is, independently, --S--R.sup.5, where each R.sup.5 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 to 4.
[0328] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 1 or 2; each R.sup.2 is, independently, CF.sub.3 or
C(CH.sub.3).sub.3; and each V.sup.1 is H and each V.sup.2 is,
independently, --S--R.sup.5, where each R.sup.5 is, independently,
--(CH.sub.2).sub.n--NH.sub.2, where each n is, independently, 1 or
2.
[0329] In some embodiments, each X is S; each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2; each R.sup.2
is, independently, CF.sub.3 or C(CH.sub.3).sub.3; and each V.sup.1
is H and each V.sup.2 is --S--R.sup.5, where each R.sup.5 is
--(CH.sub.2).sub.n--NH.sub.2, where each n is 1 or 2.
[0330] In some embodiments, each X is O or S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, or
--(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 to 4, and each R.sup.4 is, independently, H or
methyl; each R.sup.2 is, independently, halo, CF.sub.3, or
C(CH.sub.3).sub.3; and each V.sup.2 is H, and each V.sup.1 is,
independently, --N--C(.dbd.O)--R.sup.3, where each R.sup.3 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0331] In some embodiments, each X is S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.O)--R.sup.4, where
each n is, independently, 1 or 2, and each R.sup.4 is,
independently, H or methyl; each R.sup.2 is, independently, halo;
and each V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3,
where each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 4.
[0332] In some embodiments, each X is O or S; each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; each R.sup.2 is, independently, halo,
CF.sub.3, or C(CH.sub.3).sub.3; and each V.sup.2 is H, and each
V.sup.1 is, independently, --N--C(.dbd.O)--R.sup.3, where each
R.sup.3 is, independently, --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0333] In some embodiments, each X is O or S; each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 or 2;
each R.sup.2 is halo, CF.sub.3, or C(CH.sub.3).sub.3; and each
V.sup.2 is H, and each V.sup.1 is --N--C(.dbd.O)--R.sup.3, where
each R.sup.3 is --(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 3 or
4.
[0334] In some embodiments, each X is, independently, S or
S(.dbd.O).sub.2; each R.sup.1 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.p--NH--C(.dbd.O)--R.sup.4, where each n is,
independently, 1 or 2, and each R.sup.4 is, independently,
--(CH.sub.2).sub.p--NH.sub.2, where each p is, independently, 1 or
2; each R.sup.2 is, independently, halo or CF.sub.3; and each
V.sup.2 is H, and each V.sup.1 is, independently,
--N--C(.dbd.O)--R.sup.3, where each R.sup.3 is, independently,
--(CH.sub.2).sub.n--NH.sub.2 or
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 3 or 4.
[0335] In some embodiments, the compound is chosen from:
##STR00199## ##STR00200## ##STR00201## ##STR00202##
or a pharmaceutically acceptable salt thereof.
[0336] The present invention also provides compounds of Formula
VI:
##STR00203##
wherein:
[0337] each Y is, independently, O, S, or NH;
[0338] each R.sup.1 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; and
[0339] each R.sup.2 is, independently, H, halo, CF.sub.3, or
C(CH.sub.3).sub.3;
or a pharmaceutically acceptable salt thereof.
[0340] In some embodiments, each Y is, independently, O, or S; or
each Y is O or S.
[0341] In any of the above embodiments, each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 2 to 4; or each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2 to 4.
[0342] In any of the above embodiments, each R.sup.2 is,
independently, halo, CF.sub.3, or C(CH.sub.3).sub.3; or each
R.sup.2 is halo, CF.sub.3, or C(CH.sub.3).sub.3.
[0343] In some embodiments, the compound is
##STR00204##
or pharmaceutically acceptable salt thereof.
[0344] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0345] The present invention also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0346] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula VI:
##STR00205##
wherein:
[0347] each Y is, independently, O, S, or NH;
[0348] each R.sup.1 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; and
[0349] each R.sup.2 is, independently, H, halo, CF.sub.3, or
C(CH.sub.3).sub.3;
or a pharmaceutically acceptable salt thereof.
[0350] In some embodiments, each Y is, independently, O, or S; or
each Y is O or S.
[0351] In any of the above embodiments, each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 2 to 4; or each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2 to 4.
[0352] In any of the above embodiments, each R.sup.2 is,
independently, halo, CF.sub.3, or C(CH.sub.3).sub.3; or each
R.sup.2 is halo, CF.sub.3, or C(CH.sub.3).sub.3.
[0353] In some embodiments, the compound is
##STR00206##
or pharmaceutically acceptable salt thereof.
[0354] In any of the above embodiments, the malaria can be
chloroquine-sensitive or chloroquine-resistant.
[0355] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
VI:
##STR00207##
wherein:
[0356] each Y is, independently, O, S, or NH;
[0357] each R.sup.1 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4; and
[0358] each R.sup.2 is, independently, H, halo, CF.sub.3, or
C(CH.sub.3).sub.3;
or a pharmaceutically acceptable salt thereof.
[0359] In some embodiments, each Y is, independently, O, or S; or
each Y is O or S.
[0360] In any of the above embodiments, each R.sup.1 is,
independently, --(CH.sub.2).sub.n--NH.sub.2, where each n is,
independently, 2 to 4; or each R.sup.1 is
--(CH.sub.2).sub.n--NH.sub.2, where each n is 2 to 4.
[0361] In any of the above embodiments, each R.sup.2 is,
independently, halo, CF.sub.3, or C(CH.sub.3).sub.3; or each
R.sup.2 is halo, CF.sub.3, or C(CH.sub.3).sub.3.
[0362] In some embodiments, the compound is
##STR00208##
or pharmaceutically acceptable salt thereof.
[0363] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula VII:
##STR00209##
wherein:
[0364] each R.sup.1 is, independently, H, C.sub.1-C.sub.8alkyl,
C.sub.1-C.sub.8alkoxy, halo, OH, CF.sub.3, or CN;
[0365] each R.sup.2 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0366] In some embodiments, each R.sup.1 is, independently,
C.sub.1-C.sub.8alkyl, halo, OH, CF.sub.3, or CN; or each R.sup.1
is, independently, C.sub.1-C.sub.3alkyl, halo, CF.sub.3, or CN; or
each R.sup.1 is methyl or halo; or each R.sup.1 is Br, F, or
Cl.
[0367] In any of the above embodiments, each R.sup.2 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is, independently, 1 to 4; or each R.sup.2 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 to 4;
or each R.sup.2 is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2,
where each n is 1 or 2.
[0368] In some embodiments, each R.sup.1 is, independently,
C.sub.1-C.sub.8alkyl, halo, OH, CF.sub.3, or CN; and each R.sup.2
is, independently, --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2,
where each n is, independently, 1 to 4.
[0369] In some embodiments, each R.sup.1 is, independently,
C.sub.1-C.sub.3alkyl, halo, CF.sub.3, or CN; and each R.sup.2 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 to
4.
[0370] In some embodiments, each R.sup.1 is methyl or halo; and
each R.sup.2 is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is 1 or 2.
[0371] In some embodiments, the compound is
##STR00210##
or a pharmaceutically acceptable salt thereof.
[0372] In any of the above embodiments, the malaria can be
chloroquine-sensitive or chloroquine-resistant.
[0373] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
VII:
##STR00211##
wherein:
[0374] each R.sup.1 is, independently, H, C.sub.1-C.sub.8alkyl,
C.sub.1-C.sub.8alkoxy, halo, OH, CF.sub.3, or CN;
[0375] each R.sup.2 is, independently, --(CH.sub.2).sub.n--NH.sub.2
or --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4;
or a pharmaceutically acceptable salt thereof.
[0376] In some embodiments, each R.sup.1 is, independently,
C.sub.1-C.sub.8alkyl, halo, OH, CF.sub.3, or CN; or each R.sup.1
is, independently, C.sub.1-C.sub.3alkyl, halo, CF.sub.3, or CN; or
each R.sup.1 is methyl or halo; or each R.sup.1 is Br, F, or
Cl.
[0377] In any of the above embodiments, each R.sup.2 is,
independently, --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is, independently, 1 to 4; or each R.sup.2 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 to 4;
or each R.sup.2 is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2,
where each n is 1 or 2.
[0378] In some embodiments, each R.sup.1 is, independently,
C.sub.1-C.sub.8alkyl, halo, OH, CF.sub.3, or CN; and each R.sup.2
is, independently, --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2,
where each n is, independently, 1 to 4.
[0379] In some embodiments, each R.sup.1 is, independently,
C.sub.1-C.sub.3alkyl, halo, CF.sub.3, or CN; and each R.sup.2 is
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is 1 to
4.
[0380] In some embodiments, each R.sup.1 is methyl or halo; and
each R.sup.2 is --(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where
each n is 1 or 2.
[0381] In some embodiments, the compound is
##STR00212##
or a pharmaceutically acceptable salt thereof.
[0382] The present invention also provides compounds of Formula
VIII:
##STR00213##
wherein:
[0383] D is
##STR00214##
[0384] each B is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4,
##STR00215##
and
[0385] each X is, independently, O or S;
or a pharmaceutically acceptable salt thereof.
[0386] In some embodiments, D is
##STR00216##
[0387] In any of the above embodiments, each B is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0388] In any of the above embodiments, each X is S.
[0389] In some embodiments, D is
##STR00217##
each B is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 3 or 4, or
##STR00218##
and each X is S.
[0390] In some embodiments, D is
##STR00219##
each B is, independently,
##STR00220##
and each X is, independently, O or S.
[0391] In some embodiments, the compound is chosen from:
##STR00221##
or pharmaceutically acceptable salt thereof.
[0392] In some embodiments, any one or more of the above compounds
may be excluded from any of the genus of compounds described
above.
[0393] The present invention also provides compositions comprising
one or more of the compounds or salts described above and a
pharmaceutically acceptable carrier.
[0394] The present invention also provides methods of treating
malaria in an animal comprising administering to the animal a
therapeutically effective amount of a compound of Formula VIII:
##STR00222##
wherein:
[0395] D is
##STR00223##
[0396] each B is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4,
##STR00224##
and
[0397] each X is, independently, O or S;
or a pharmaceutically acceptable salt thereof.
[0398] In some embodiments, D is
##STR00225##
[0399] In any of the above embodiments, each B is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0400] In any of the above embodiments, each X is S.
[0401] In some embodiments, D is
##STR00226##
each B is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 3 or 4, or
##STR00227##
and each X is S.
[0402] In some embodiments, D is
##STR00228##
each B is, independently,
##STR00229##
and each X is, independently, O or S.
[0403] In some embodiments, the compound is chosen from:
##STR00230##
or pharmaceutically acceptable salt thereof.
[0404] In any of the above embodiments, the malaria can be
chloroquine-sensitive or chloroquine-resistant.
[0405] The present invention also provides methods of killing or
inhibiting the growth of a Plasmodium species comprising contacting
the species with an effective amount of a compound of Formula
VIII:
##STR00231##
wherein:
[0406] D is
##STR00232##
[0407] each B is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4,
##STR00233##
and
[0408] each X is, independently, O or S;
or a pharmaceutically acceptable salt thereof.
[0409] In some embodiments, D is
##STR00234##
[0410] In any of the above embodiments, each B is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 1 to 4.
[0411] In any of the above embodiments, each X is S.
[0412] In some embodiments, D is
##STR00235##
each B is, independently,
--(CH.sub.2).sub.n--NH--C(.dbd.NH)NH.sub.2, where each n is,
independently, 3 or 4, or
##STR00236##
and each X is S.
[0413] In some embodiments, D is
##STR00237##
each B is, independently,
##STR00238##
and each X is, independently, O or S.
[0414] In some embodiments, the compound is chosen from:
##STR00239##
or pharmaceutically acceptable salt thereof.
[0415] It is to be understood that within any particular Formula,
any one embodiment can be combined with any other embodiment(s), as
deemed appropriate.
[0416] In some embodiments, the anti-malarial compound(s) can be
chosen from one or more of the compounds (i.e., genuses,
sub-genuses, and species) disclosed in U.S. Patent Application
Publication Nos. US 2005/0287108 and/or US 2006/0041023, each of
which is incorporated herein by reference in its entirety. The
methods described herein can also be carried out using any one or
more of the compounds disclosed as a genus, sub-genus, or species
of U.S. Patent Application Publication Nos. US 2005/0287108 and/or
US 2006/0041023.
[0417] Some of the compounds of the present invention may be
capable of adopting amphiphilic conformations that allow for the
segregation of polar and nonpolar regions of the molecule into
different spatial regions and provide the basis for a number of
uses. For example, some anti-malarial compounds may adopt
amphiphilic conformations that are capable of disrupting the
integrity of the cell membrane of microorganisms, resulting in the
inhibition of growth or the death of, for example, Plasmodium
species.
[0418] The anti-malarial compounds can be useful as anti-malarial
agents in a number of applications. For example, anti-malarial
compounds can be used therapeutically to treat malaria in animals,
including humans and non-human vertebrates such as wild, domestic
and farm animals. The malarial infection in an animal can be
treated by administering to the animal an effective amount of an
anti-malarial compound, or a pharmaceutical composition comprising
the same. The anti-malarial compound, or composition thereof, can
be administered systemically or topically and can be administered
to any body site or tissue.
[0419] Although the anti-malarial compounds are suitable, other
functional groups can be incorporated into the compound with an
expectation of similar results. In particular, thioamides and
thioesters are anticipated to have very similar properties. The
distance between aromatic rings can impact the geometrical pattern
of the compound and this distance can be altered by incorporating
aliphatic chains of varying length, which can be optionally
substituted or can comprise an amino acid, a dicarboxylic acid or a
diamine. The distance between and the relative orientation of
monomers within the compounds can also be altered by replacing the
amide bond with a surrogate having additional atoms. Thus,
replacing a carbonyl group with a dicarbonyl alters the distance
between the monomers and the propensity of dicarbonyl unit to adopt
an anti arrangement of the two carbonyl moiety and alter the
periodicity of the compound. Pyromellitic anhydride represents
still another alternative to simple amide linkages which can alter
the conformation and physical properties of the compound. Modern
methods of solid phase organic chemistry (E. Atherton and R. C.
Sheppard, Solid Phase Peptide Synthesis A Practical Approach IRL
Press Oxford 1989) now allow the synthesis of homodisperse
compounds with molecular weights approaching 5,000 Daltons. Other
substitution patterns are equally effective.
[0420] The term "malarialcidal" as used herein means that the
compound inhibits, prevents, or destroys the growth or
proliferation of a Plasmodium species.
[0421] The anti-malarial compounds can be incorporated into
polishes, paints, sprays, or detergents formulated for application
to surfaces to inhibit the growth of a Plasmodium species thereon.
These surfaces include, but are not limited to, surfaces such as,
countertops, desks, chairs, laboratory benches, tables, floors, bed
stands, tools or equipment, doorknobs, and windows. The
anti-malarial compounds can also be incorporated into soaps and
hand lotions. The present cleansers, polishes, paints, sprays,
soaps, or detergents contain an anti-malarial compound that
provides a malarialstatic property to them. The anti-malarial
compounds can optionally contain suitable solvent(s), carrier(s),
thickeners, pigments, fragrances, deodorizers, emulsifiers,
surfactants, wetting agents, waxes, or oils. For example, in some
aspects, the anti-malarial compounds can be incorporated into a
formulation for external use as a pharmaceutically acceptable skin
cleanser, particularly for the surfaces of human hands. Cleansers,
polishes, paints, sprays, soaps, hand lotions, and detergents and
the like containing the anti-malarial compounds can be useful in
homes and institutions, particularly but not exclusively, in
hospital settings for the prevention of nosocomial infections.
[0422] In some aspects, the anti-malarial compounds include
derivatives referred to as prodrugs. The expression "prodrug"
denotes a derivative of a known direct acting drug, which
derivative has enhanced delivery characteristics and therapeutic
value as compared to the drug, and is transformed into the active
drug by an enzymatic or chemical process.
[0423] It is understood that the present invention encompasses the
use, where applicable, of stereoisomers, diastereomers and optical
isomers of the anti-malarial compounds, as well as mixtures
thereof, for treating malarial infections, an/or killing or
inhibiting the growth of a Plasmodium species. Additionally, it is
understood that stereoisomers, diastereomers, and optical isomers
of the anti-malarial compounds, and mixtures thereof, are within
the scope of the invention. By way of non-limiting example, the
mixture may be a racemate or the mixture may comprise unequal
proportions of one particular stereoisomer over the other.
Additionally, the anti-malarial compounds can be provided as a
substantially pure stereoisomers, diastereomers and optical
isomers.
[0424] In another aspect, the anti-malarial compounds can be
provided in the form of an acceptable salt (i.e., a
pharmaceutically acceptable salt) for treating malarial infections,
and/or killing or inhibiting the growth of a Plasmodium species.
Salts can be provided for pharmaceutical use, or as an intermediate
in preparing the pharmaceutically desired form of the anti-malarial
compounds. One salt that can be considered to be acceptable is the
hydrochloride acid addition salt. Hydrochloride acid addition salts
are often acceptable salts when the pharmaceutically active agent
has an amine group that can be protonated. Since an anti-malarial
compound may be polyionic, such as a polyamine, the acceptable salt
can be provided in the form of a poly(amine hydrochloride).
[0425] Polyamides and polyesters that are useful can be prepared by
typical condensation polymerization and addition polymerization
processes. See, for example, G. Odian, Principles of
Polymerization, John Wiley & Sons, Third Edition (1991), M.
Steven, Polymer Chemistry, Oxford University Press (1999). Most
commonly the polyamides are prepared by (a) thermal dehydration of
amine salts of carboxylic acids, (b) reaction of acid chlorides
with amines and (c) aminolysis of esters. Methods (a) and (c) are
of limited use in polymerizations of aniline derivatives which are
generally prepared utilizing acid chlorides. The skilled chemist,
however, will recognize that there are many alternative active
acylating agents, for example phosphoryl anhydrides, active esters
or azides, which may replace an acid chloride and which, depending
of the particular polymer being prepared, may be superior to an
acid chloride. The acid chloride route is probably the most
versatile and baa been used extensively for the synthesis of
aromatic polyamides.
[0426] Homopolymers derived from substituted aminobenzoic acid
derivatives can also prepared in a stepwise fashion. A stepwise
process comprises coupling an N-protected amino acid to an amine
(or hydroxy group) and subsequently removing the amine-protecting
group and repeating the process. These techniques have been highly
refined for synthesis of specific peptides, allow for the synthesis
of specific sequences, and both solid-phase and solution techniques
for peptide synthesis are directly applicable to the present
invention. An alternative embodiment of the present invention is
the corresponding polysulfonamides that can be prepared in
analogous fashion by substituting sulfonyl chlorides for carboxylic
acid chlorides.
[0427] The most common method for the preparation of polyureas is
the reaction of diamines with diisocyanates (Yamaguchi, et al.,
Polym. Bull., 2000, 44, 247). This exothermic reaction can be
carried out by solution techniques or by interfacial techniques.
One skilled in organic and polymer chemistry will appreciate that
the diisocyanate can be replaced with a variety of other
bis-acylating agents e.g., phosgene or N,N'-(diimidazolyl)carbonyl,
with similar results. Polyurethanes are prepared by comparable
techniques using a diisocyanate and a dialcohol or by reaction of a
diamine with a bis-chloroformate.
[0428] The syntheses of the anti-malarial compounds can be carried
out by routine and/or known methods such as those disclosed in, for
example, U.S. Patent Application Publication Nos. US 2005/0287108
and US 2006/0041023, each of which is incorporated herein by
reference in its entirety. Numerous pathways are available to
incorporate polar and nonpolar side chains. Phenolic groups on the
monomer can be alkylated. Alkylation of the commercially available
phenol will be accomplished with standard Williamson ether
synthesis for the non-polar side chain with ethyl bromide as the
alkylating agent. Polar sidechains can be introduced with
bifunctional alkylating agents such as BOC--NH(CH.sub.2).sub.2Br.
Alternatively, the phenol group can be alkylated to install the
desired polar side chain function by employing the Mitsonobu
reaction with BOC--NH(CH.sub.2).sub.2--OH, triphenyl phosphine, and
diethyl acetylenedicarboxylate. Standard conditions for reduction
of the nitro groups and hydrolysis of the ester afford the amino
acid. With the aniline and benzoic acid in hand, coupling can be
effected under a variety of conditions. Alternatively, the hydroxy
group of the (di)nitrophenol can be converted to a leaving group
and a functionality introduced under nucleophilic aromatic
substitution conditions. Other potential scaffolds that can be
prepared with similar sequences are methyl
2-nitro-4-hydroxybenzoate and methyl 2-hydroxy-4-nitrobenzoate.
[0429] The anti-malarial compounds can also be designed using
computer-aided computational techniques, such as de novo design
techniques, to embody the amphiphilic properties. In general, de
novo design of anti-malarial compounds is performed by defining a
three-dimensional framework of the backbone assembled from a
repeating sequence of monomers using molecular dynamics and quantum
force field calculations. Next, side groups are computationally
grafted onto the backbone to maximize diversity and maintain
drug-like properties. The best combinations of functional groups
are then computationally selected to produce a cationic,
amphiphilic structures. Representative compounds can be synthesized
from this selected library to verify structures and test their
biological activity. Novel molecular dynamic and coarse grain
modeling programs have also been developed for this approach
because existing force fields developed for biological molecules,
such as peptides, were unreliable in these oligomer applications
(Car, R., and Parrinello, M., Phys. Rev. Lett., 55:2471-2474
(1985); Siepmann, J. I., and Frenkel, D., Mol. Phys. 75:59-70
(1992); Martin, M. G., and Siepmann, J. I., J. Phys. Chem. B
103:4508-4517 (1999); Brooks, B. R., et al., J. Comp. Chem.
4:187-217 (1983)). Several chemical structural series of compounds
have been prepared. See, for example, WO 02/100295 A2, which is
incorporated herein by reference in its entirety. The anti-malarial
compounds can be prepared in a similar manner. Molecular dynamic
and coarse grain modeling programs can be used for a design
approach. See, for example, U.S. Patent Application No. US
2004-0107056, and U.S. Patent Application No. US 2004-0102941, each
of which is incorporated herein by reference in its entirety.
[0430] After verifying the suitability of the force field by
comparing computed predictions of the structure and thermodynamic
properties to molecules that have similar torsional patterns and
for which experimental data are available, the fitted torsions can
then be combined with bond stretching, bending, one-four, van der
Waals, and electrostatic potentials borrowed from the CHARMM
(Brooks, B. R., et al., J. Comp. Chem. 4:187-217 (1983)) and TraPPE
(Martin, M. G., and Siepmann, J. I., J. Phys. Chem. B 103:4508-4517
(1999); Wick, C. D., et al., J. Phys. Chem. B 104:3093-3104 (2000))
molecular dynamics force fields. To identify conformations that can
adopt periodic folding patterns with polar groups and apolar groups
lined up on the opposite sides, initial structures can be obtained
with the Gaussian package (Frisch, M., et al., Gaussian 98
(revision A.7) Gaussian Inc., Pittsburgh, Pa. 1998). Then, the
parallelized plane-wave Car-Parrinello CP-MD (Car, R., and
Parrinello, M., Phys. Rev. Lett. 55:2471-2474 (1985)) program, (cf.
Rothlisberger, U., et al., J. Chem. Phys. 3692-3700 (1996)) can be
used to obtain energies at the minimum and constrained geometries.
The conformations of the compounds without side-chains can be
investigated in the gas phase. Both MD and MC methods can be used
to sample the conformations. The former is useful for global
motions of the compound. With biasing techniques (Siepmann, J. I.,
and Frenkel, D., Mol. Phys. 75:59-70 (1992); Martin, M. G., and
Siepmann, J. I., J. Phys. Chem. B 103:4508-4517 (1999); Vlugt, T.
J. H., et al. Mol. Phys. 94:727-733 (1998)), the latter allows
efficient sampling for compounds with multiple local minimum
configurations that are separated by relatively large barriers.
[0431] The potential conformations are examined for positions to
attach pendant groups that will impart amphiphilic character to the
secondary structure. Compounds selected from the gas phase studies
with suitable backbone conformations and with side-chains at the
optimal positions to introduce amphiphilicity can be further
evaluated in a model interfacial system. n-hexane/water can be
chosen because it is simple and cheap for calculations while it
mimics well the lipid/water bilayer environment. Compound secondary
structures that require inter-compound interactions can be
identified by repeating the above-mentioned calculations using a
periodically repeated series of unit cells of various symmetries
(so called variable cell molecular dynamics or Monte Carlo
technique) with or without solvent. The results of these
calculations can guide the selection of candidates for
synthesis.
[0432] An example of the design, synthesis, and testing of
arylamide polymers and oligomers, a related group of compounds of
the invention, is presented in Tew, G. N., et al., Proc. Natl.
Acad. Sci. USA 99:5110-5114 (2002), which is incorporated herein by
reference in its entirety.
[0433] The anti-malarial compounds can be synthesized by
solid-phase synthetic procedures well know to those of skill in the
art. See, for example, Tew et al. (Tew, G. N., et al., Proc. Natl.
Acad. Sci. USA 99:5110-5114 (2002)). See also Barany, G., et al.,
Int. J. Pept. Prot. Res. 30:705-739 (1987); Solid-phase Synthesis:
A Practical Guide, Kates, S. A., and Albericio, F., eds., Marcel
Dekker, New York (2000); and Dorwald, F. Z., Organic Synthesis on
Solid Phase: Supports, Linkers, Reactions, 2nd Ed., Wiley-VCH,
Weinheim (2002).
[0434] One of skill in the art will recognize that the
anti-malarial compounds can be tested for anti-malarial activity by
methods well known to those of skill in the art. Any compound found
to be active can be purified to homogeneity and re-tested to obtain
an accurate IC.sub.50.
[0435] The anti-malarial compounds can be administered in any
conventional manner by any route where they are active.
Administration can be systemic, topical, or oral. For example,
administration can be, but is not limited to, parenteral,
subcutaneous, intravenous, intramuscular, intraperitoneal,
transdermal, oral, buccal, or ocular routes, or intravaginally, by
inhalation, by depot injections, or by implants. Thus, modes of
administration for the anti-malarial compounds (either alone or in
combination with other pharmaceuticals) can be, but are not limited
to, sublingual, injectable (including short-acting, depot, implant
and pellet forms injected subcutaneously or intramuscularly), or by
use of vaginal creams, suppositories, pessaries, vaginal rings,
rectal suppositories, intrauterine devices, and transdermal forms
such as patches and creams. The selection of the specific route of
administration and the dose regimen is to be adjusted or titrated
by the clinician according to methods known to the clinician to
obtain the desired clinical response.
[0436] The amount of any particular anti-malarial compound to be
administered is that amount which is therapeutically effective. The
dosage to be administered will depend on the characteristics of the
subject being treated, e.g., the particular animal treated, age,
weight, health, types of concurrent treatment, if any, and
frequency of treatments, and can be easily determined by one of
skill in the art (e.g., by the clinician). The amount of an
anti-malarial compound described herein that will be effective in
the treatment of malaria will depend on the nature of the malaria,
and can be determined by standard clinical techniques. In addition,
in vitro or in vivo assays may optionally be employed to help
identify optimal dosage ranges. The precise dose to be employed in
the compositions will also depend on the route of administration,
and the seriousness of the disorder, and should be decided
according to the judgment of the practitioner and each patient's
circumstances. However, a suitable dosage range for oral
administration is, generally, from about 0.001 milligram to about
200 milligrams per kilogram body weight. In some embodiments, the
oral dose is from about 0.01 milligram to 100 milligrams per
kilogram body weight, from about 0.01 milligram to about 70
milligrams per kilogram body weight, from about 0.1 milligram to
about 50 milligrams per kilogram body weight, from 0.5 milligram to
about 20 milligrams per kilogram body weight, or from about 1
milligram to about 10 milligrams per kilogram body weight. In some
embodiments, the oral dose is about 5 milligrams per kilogram body
weight.
[0437] The pharmaceutical compositions and/or formulations
containing the anti-malarial compounds and a suitable carrier can
be solid dosage forms which include, but are not limited to,
tablets, capsules, cachets, pellets, pills, powders and granules;
topical dosage forms which include, but are not limited to,
solutions, powders, fluid emulsions, fluid suspensions,
semi-solids, ointments, pastes, creams, gels and jellies, and
foams; and parenteral dosage forms which include, but are not
limited to, solutions, suspensions, emulsions, and dry powder;
comprising an effective amount of a anti-malarial compound. It is
also known in the art that the active ingredients can be contained
in such formulations with pharmaceutically acceptable diluents,
fillers, disintegrants, binders, lubricants, surfactants,
hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers,
humectants, moisturizers, solubilizers, preservatives and the like.
The means and methods for administration are known in the art and
an artisan can refer to various pharmacologic references for
guidance. For example, Modern Pharmaceutics, Banker & Rhodes,
Marcel Dekker, Inc. (1979); and Goodman & Gilman's The
Pharmaceutical Basis of Therapeutics, 6th Edition, MacMillan
Publishing Co., New York (1980) can be consulted.
[0438] The anti-malarial compounds can be formulated for parenteral
administration by injection, e.g., by bolus injection or continuous
infusion. The anti-malarial compounds can be administered by
continuous infusion subcutaneously over a period of about 15
minutes to about 24 hours. Formulations for injection can be
presented in unit dosage form, e.g., in ampoules or in multi-dose
containers, with an added preservative. The compositions can take
such forms as suspensions, solutions or emulsions in oily or
aqueous vehicles, and can contain formulatory agents such as
suspending, stabilizing and/or dispersing agents.
[0439] For oral administration, the anti-malarial compounds can be
formulated readily by combining these compounds with
pharmaceutically acceptable carriers well known in the art. Such
carriers enable the anti-malarial compounds to be formulated as
tablets, pills, dragees, capsules, liquids, gels, syrups, slurries,
suspensions and the like, for oral ingestion by a patient to be
treated. Pharmaceutical preparations for oral use can be obtained
by, for example, adding a solid excipient, optionally grinding the
resulting mixture, and processing the mixture of granules, after
adding suitable auxiliaries, if desired, to obtain tablets or
dragee cores. Suitable excipients include, but are not limited to,
fillers such as sugars, including, but not limited to, lactose,
sucrose, mannitol, and sorbitol; cellulose preparations such as,
but not limited to, maize starch, wheat starch, rice starch, potato
starch, gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and
polyvinylpyrrolidone (PVP). If desired, disintegrating agents can
be added, such as, but not limited to, the cross-linked polyvinyl
pyrrolidone, agar, or alginic acid or a salt thereof such as sodium
alginate.
[0440] Dragee cores can be provided with suitable coatings. For
this purpose, concentrated sugar solutions can be used, which can
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments can be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses.
[0441] Pharmaceutical preparations which can be used orally
include, but are not limited to, push-fit capsules made of gelatin,
as well as soft, sealed capsules made of gelatin and a plasticizer,
such as glycerol or sorbitol. The push-fit capsules can contain the
active ingredients in admixture with filler such as, e.g., lactose,
binders such as, e.g., starches, and/or lubricants such as, e.g.,
talc or magnesium stearate and, optionally, stabilizers. In soft
capsules, the active compounds can be dissolved or suspended in
suitable liquids, such as fatty oils, liquid paraffin, or liquid
polyethylene glycols. In addition, stabilizers can be added. All
formulations for oral administration should be in dosages suitable
for such administration.
[0442] For buccal administration, the compositions can take the
form of, e.g., tablets or lozenges formulated in a conventional
manner.
[0443] For administration by inhalation, the anti-malarial
compounds for use according to the present invention are
conveniently delivered in the form of an aerosol spray presentation
from pressurized packs or a nebulizer, with the use of a suitable
propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In
the case of a pressurized aerosol the dosage unit can be determined
by providing a valve to deliver a metered amount. Capsules and
cartridges of, e.g., gelatin for use in an inhaler or insufflator
can be formulated containing a powder mix of the compound and a
suitable powder base such as lactose or starch.
[0444] The anti-malarial compounds can also be formulated in rectal
compositions such as suppositories or retention enemas, e.g.,
containing conventional suppository bases such as cocoa butter or
other glycerides.
[0445] In addition to the formulations described previously, the
anti-malarial compounds can also be formulated as a depot
preparation. Such long acting formulations can be administered by
implantation (for example subcutaneously or intramuscularly) or by
intramuscular injection. Depot injections can be administered at
about 1 to about 6 months or longer intervals. Thus, for example,
the anti-malarial compounds can be formulated with suitable
polymeric or hydrophobic materials (for example as an emulsion in
an acceptable oil) or ion exchange resins, or as sparingly soluble
derivatives, for example, as a sparingly soluble salt.
[0446] In transdermal administration, the anti-malarial compounds
can be applied to a plaster, or can be applied by transdermal,
therapeutic systems that are consequently supplied to the
organism.
[0447] The pharmaceutical compositions comprising the anti-malarial
compounds also can comprise suitable solid or gel phase carriers or
excipients. Examples of such carriers or excipients include, but
are not limited to, calcium carbonate, calcium phosphate, various
sugars, starches, cellulose derivatives, gelatin, and polymers such
as, e.g., polyethylene glycols.
[0448] In another embodiment, the anti-malarial compounds described
herein can be delivered in a vesicle, in particular a liposome
(see, Langer, Science, 1990, 249, 1527-1533; Treat et al., in
Liposomes in the Therapy of Infectious Disease and Cancer,
Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365
(1989); Lopez-Berestein, ibid., pp. 317-327; see generally
ibid.).
[0449] In yet another embodiment, the anti-malarial compounds
described herein can be delivered in a controlled release system.
In one embodiment, a pump may be used (see Langer, supra; Sefton,
CRC Crit. Ref. Biomed. Eng., 1987, 14, 201; Buchwald et al.,
Surgery, 1980, 88, 507 Saudek et al., N. Engl. J. Med., 1989, 321,
574). In another embodiment, polymeric materials can be used (see
Medical Applications of Controlled Release, Langer and Wise (eds.),
CRC Pres., Boca Raton, Fla. (1974); Controlled Drug
Bioavailability, Drug Product Design and Performance, Smolen and
Ball (eds.), Wiley, New York (1984); Ranger et al., J. Macromol.
Sci. Rev. Macromol. Chem., 1983, 23, 61; see, also Levy et al.,
Science, 1985, 228, 190; During et al., Ann. Neurol., 1989, 25,
351; Howard et al., J. Neurosurg., 1989, 71, 105). In yet another
embodiment, a controlled-release system can be placed in proximity
of the target of the anti-malarial compounds described herein,
e.g., the liver, thus requiring only a fraction of the systemic
dose (see, e.g., Goodson, in Medical Applications of Controlled
Release, supra, vol. 2, pp. 115-138 (1984)). Other
controlled-release systems discussed in the review by Langer,
Science, 1990, 249, 1527-1533) may be used.
[0450] The anti-malarial compounds can also be administered in
combination with other active ingredients such as, for example,
antibiotics, including, but not limited to, vancomycin,
ciprofloxacin, merapenem, oxicillin, and amikacin. The
anti-malarial compounds can also be administered in combination
with other anti-malarial compounds such as, for example, any one or
more of artemisinin, quinine, artesunate,
sulfadoxine-pyrimethamine, hydroxychloroquine, chloroquine,
amodiaquine, pyrimethamine, sulphadoxine, proguanil, mefloquine,
atovaquone, primaquine, halofantrine, doxycycline, clindamycin.
[0451] Thus, the present invention also provides methods of
treating malaria in an animal comprising administering to the
animal in need thereof an effective amount of an anti-malarial
compound or a slat thereof. The present invention also provides
methods of treating malaria in an animal comprising administering
to the animal in need thereof a composition comprising an
anti-malarial compound, or a slat thereof. The present invention
also provides methods of killing or inhibiting the growth of a
Plasmodium species comprising contacting the species with an
effective amount of an anti-malarial compound, or salt thereof. The
present invention also provides methods of killing or inhibiting
the growth of a Plasmodium species comprising contacting the
species with a composition comprising an anti-malarial compound, or
salt thereof. The present invention also provides methods of
killing or inhibiting the growth of a chloroquine-sensitive or
chloroquine-resistant Plasmodium species comprising contacting the
species with an effective amount of an anti-malarial compound, or
salt thereof. The present invention also provides methods of
killing or inhibiting the growth of a chloroquine-sensitive or
chloroquine-resistant Plasmodium species comprising contacting the
species with a composition comprising an anti-malarial compound, or
salt thereof. The present invention also provides methods of
disrupting a food vacuole of a Plasmodium species comprising
contacting the species with an effective amount of an anti-malarial
compound, or salt thereof. The present invention also provides
methods of disrupting a food vacuole of a Plasmodium species
comprising contacting the species with a composition comprising an
anti-malarial compound, or salt thereof.
[0452] An "animal in need thereof" is an animal that has been
diagnosed with malaria, an animal who is suspected of having
malaria, and/or an animal that is in an environment or will be
traveling to an environment in which malaria is prevelant.
[0453] The present invention also provides anti-malarial compounds,
or a salt thereof, or compositions comprising the same, for use in
treating a malarial infection in an animal. The present invention
also provides anti-malarial compounds, or a salt thereof, or
compositions comprising the same, for use in killing or inhibiting
the growth of a Plasmodium species. The present invention also
provides anti-malarial compounds, or a salt thereof, or
compositions comprising the same, for use in preparation of a
medicament for treating a malarial infection in an animal. The
present invention also provides anti-malarial compounds, or a salt
thereof, or compositions comprising the same, for use in
preparation of a medicament for killing or inhibiting the growth of
a Plasmodium species.
[0454] The anti-malarial compounds described herein can be combined
with one, two, or three other anti-malarial compounds described
herein to form a cocktail. This cocktail can also include other
anti-malarial compounds.
[0455] In order that the invention disclosed herein may be more
efficiently understood, examples are provided below. It should be
understood that these examples are for illustrative purposes only
and are not to be construed as limiting the invention in any
manner.
EXAMPLES
Example 1
Synthesis of Compounds 142 and 149
##STR00240## ##STR00241##
[0457] Step 1: The diamine (0.1 mmol) and
({[(tert-butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methyl}amino)pe-
ntanoic acid (4 equivalence) were dissolved in 3 mL of pyridine and
cooled to 0.degree. C. The solution was added POCl.sub.3 (4 equiv.)
dropwise and stirred at 0.degree. C. for 1.5 hours. The reaction
was quenched with ice water. The solvent was removed on a
rotovap.
[0458] Step 2: The product from step 1 was treated with 50%
trifluoroacetic acid (TFA) in dichloromethane (DCM). The product
was purified by reverse phase chromatography.
Example 2
Synthesis of Compounds 109, 111, and 144
##STR00242##
[0460] Step 1: 319.6 mg of 4,4-dihydroxyphenyl in 4.0 ml of
dimethylformamide (DMF) were sequentially added to 839.0 mg of
K.sub.2CO.sub.3, and 1.3166 g of 3,5-dinitrobenzotrifluoride. The
reaction mixture was heated to 125.degree. C. with stirring for
overnight. TLC analysis indicated the starting material was
consumed. The reaction was quenched with water and extracted with
ethyl acetate (EtOAc) twice. The organic phase was washed with
water, brine and dried with sodium sulfate before being
concentrated under reduced pressure. The product was purified by
column chromatography with a yield of 865.6 mg (69%).
[0461] Step 2: 312.3 mg of the product formed in step 1 in 5.0 ml
of MeOH was sequentially added to 365.3 mg of NH.sub.4Cl, and 400.2
mg of Zinc dust. The reaction mixture was irradiated under
microwave at 115.degree. C. for 20 minutes. LCMS analysis indicated
the starting material was consumed. The reaction mixture was
filtered and concentrated. The residue was quenched with water and
extracted with EtOAc twice. The organic phase was washed with
water, brine and dried with sodium sulfate before being
concentrated under reduced pressure. The crude product was under
high vacuum for 6 hours and was used without further
purification.
[0462] Step 3: 44.9 mg of diamine formed in step 2 was added to
(2-oxo-ethyl)-carbamic acid tert-butyl ester (2 equiv. for
compounds 109 and 111, 1 equiv. for compound 144) in 1.5 ml of
anhydrous EtOH. The reaction mixture was sequentially added 3 drops
of HOAc and 78.6 mg of NaCNBH.sub.3. The reaction mixture was
stirred at room temperature overnight. LCMS analysis indicated the
starting material was consumed. The reaction mixture was
concentrated and the residue was quenched with water and extracted
with EtOAc twice. The organic phase was washed with water, brine
and dried with sodium sulfate before being concentrated under
reduced pressure. The product was purified by column chromatography
with a yield of 72.3 mg (97%).
[0463] Step 4: 41.3 mg of Boc-protected diamine formed in step 3 in
1.5 ml of DCM was added 1.5 ml of TFA and the reaction mixture was
stirred at room temperature for 45 minutes. LCMS analysis indicated
the starting material was consumed. The reaction mixture was
concentrated and the residue was washed with ether twice. The white
powder in 2 ml of ether was further sonicated for 10 minutes. The
white solid was then washed with ether twice and was under high
vacuum for 12 hours. The yield was 39.6 mg.
Example 3
Synthesis of Compounds 148 and 147
##STR00243## ##STR00244##
[0465] Step 1: 1.1071 g of
bis-(4,4-dihydroxyphenyl)-bis-(trifluoromethyl)-methane in 4.0 ml
of DMF were sequentially added 1.36 g of K.sub.2CO.sub.3, and
1.2777 g of 4-fluoro3-trifluoromethylbenzealdehyde. The reaction
mixture was heated to 130.degree. C. and stirred for 6 hours. The
reaction was quenched with water and extracted with EtOAc twice.
The organic phase was washed with water, brine and dried with
sodium sulfate before was concentrated under reduced pressure. The
product was purified by column chromatography with a yield of 400.0
mg.
[0466] Step 2: 71.4 mg of dialdehyde formed in step 1 in 3.0 ml of
dichloroethane was sequentially added 241.8 mg of
piperazine-1-carboxylic acid tert-butyl ester, and 257.8 mg of
NaBH(OAc).sub.3. The reaction mixture was stirred at room
temperature overnight. LCMS analysis indicated the starting
material was consumed. The reaction mixture was concentrated and
the residue was quenched with Na.sub.2CO.sub.3 solution and
extracted with EtOAc twice. The organic phase was washed with
water, brine and dried with sodium sulfate before being
concentrated under reduced pressure. The product was purified by
column chromatography with a yield of 113.7 mg (91%).
[0467] Step 3: 73.0 mg of Boc-protected diamine formed in step 2 in
2.0 ml of DCM was added 2.0 ml of TFA and the reaction mixture was
stirred at room temperatue for 45 minutes. LCMS analysis indicated
the starting material was consumed. The reaction mixture was
concentrated and the residue was washed with ether twice. The white
powder in 2 ml of ether was further sonicated for 10 minutes. The
white solid was then washed with ether twice and was under high
vacuum for 12 hours. The yield was 70.3 mg.
Example 4
Synthesis of Compounds 145 and 146
##STR00245##
[0469] Compound 145 was synthesized using a similar procedure for
compound 147. The starting materials for step 1 are
4-[(4-hydroxyphenyl)sulfonyl]phenol and
3-fluoro-4-trifluoromethylbenzaldehyde.
##STR00246##
[0470] Compound 146 was synthesized using a similar procedure for
compound 147. The starting materials for step 1 are
4-[(4-hydroxyphenyl)sulfonyl]phenol and
3-fluoro-5-trifluoromethylbenzaldehyde.
Example 5
Synthesis of Compound 143
##STR00247##
[0472] Step 1: The starting material was made using the same
procedure as step 1 of the synthesis of compound 145. 60.6 mg of
dialdehyde formed in coupling reaction in 2.0 ml of EtOH was
sequentially added 220.3 mg of NH.sub.2OH.HCl, 0.5 ml of water, and
0.1 ml of pyridine. The reaction mixture was irradiated under
microwave at 120.degree. C. for 30 minutes. LCMS analysis indicated
the starting material was consumed. The reaction mixture was
concentrated and the residue was quenched with 2 ml of water. The
crude product was filtered and used for the next step without
further purification.
[0473] Step 2: The crude product formed in step 1 above was
dissolved in 4 ml of HOAc. Zn dust (321.3 mg) was added in two
portions. The resulting mixture was heated at 60.degree. C. for 6
hours. The reaction mixture was filtered and concentrated. The
residue was charged with 5 ml of tetrahydrofuran (THF), 0.3 ml of
triethylamine (TEA) and 100.6 mg of Boc anhydride. The reaction
mixture was stirred at room temperature for 4 hours and was
quenched with Na.sub.2CO.sub.3 solution and extracted with EtOAc
twice. The organic phase was washed with water, brine and dried
with sodium sulfate before being concentrated under reduced
pressure. The product was purified by column chromatography with a
yield of 67.8 mg (82%, two steps).
[0474] Step 3: 42.1 mg of Boc-protected diamine formed in step 2 in
2.0 ml of DCM was added 2.0 ml of TFA and the reaction mixture was
stirred at room temperature for 45 minutes. LCMS analysis indicated
the starting material was consumed. The reaction mixture was
concentrated and the residue was washed with ether twice. The white
powder in 2 ml of ether was further sonicated for 10 minutes. The
white solid was then washed with ether twice and was under high
vacuum for 12 hours. The yield was 30.2 mg.
Example 6
Synthesis of Compounds 101, 102, 107, 113, 114, 121, 123, and
124
##STR00248## ##STR00249## ##STR00250##
[0476] Step 1: Dianiline (0.15 mol) and diacid (0.062 mol) were
combined with pyridine (121 mL) and a stir bar in a nitrogen purged
2 L RBF and stirred to a suspension with small pieces for 15
minutes. Then EDCI (0.185 mol) was added and the mixture was
stirred at ambient temperature for 7.5 hours. The reaction was
quenched with water (810 mL). The product was purified by column
chromatography or trituation using heptane and ethyl acetate.
[0477] Step 2: Product from step 1 (0.179 mol) and
({[(tert-butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methyl}amino)pe-
ntanoic acid (0.734 mol) were dissolved in 2.1 L dry pyridine. The
solution was cooled to -20.degree. C. to 0.degree. C. To the
solution, POCl.sub.3 (0.716 mol) was slowly added over 30 minutes.
The reaction mixture was stirred for 2 hours at -20.degree. C. to
0.degree. C. and then it was allowed to warm to room temperature
and stirred for another 2 hours. Ice water (8 L) was added to
quench the reaction. The precipitated solid was collected and
purified by either column chromatography or trituration.
[0478] Step 3: Product from step 3 (98.4 mmol) was dissolved in 465
mL of formic acid. The solution was added 246 mL of 4M HCl in
dioxane and stirred at room temperature for 10 hours. To this
reaction mixture was added 1-butanol (2.5 L). The resulting
precipitate was collected by filtration and purified by reverse
phase column chromatography.
Example 7
Synthesis of Compounds 122 and 126-129
##STR00251## ##STR00252## ##STR00253## ##STR00254##
[0480] Step 1: The starting diamine is made using similar method as
step 1 of common synthesis 2. Diamine was treated with 50%
Trifluoroacetic acid in dichloromethane for 2 hours. The resulting
solution was concentrated to an oil and triturated with cold
diethyl ether. The solid was collected by filtration.
[0481] Step 2: Product from step 1 (1 mmol) and
N,N'-bis-Boc-1-guanylpyrazole (2 mmol) were dissolved in 10 mL of
methanol followed by 2 equivalence of mL of disopropylethylamine.
The mixture was stirred overnight at room temperature before the
solvent was removed by rotovap. The product was purified by column
chromatography.
[0482] Step 3: This step was carried out similar as step 2 of
common synthesis 2 using product from step 2 and
N-tert-butoxycarbonylamino-pentanoic acid.
[0483] Step 4: This step is the same as step 3 in common synthesis
2.
Example 8
Synthesis of Compound 108
##STR00255##
[0485] The synthesis is similar as common synthesis 2 except in
step 3,
({[(tert-butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methyl}amino)pr-
opanoic acid was used.
Example 9
Synthesis of Compound 125
##STR00256## ##STR00257##
[0487] Step 1 and 2 are similar to step 1 and 2 of the synthesis of
compound 101.
[0488] Step 3: Product from step 2 was treated with 20% piperidine
in DMF. After diluted with ethyl acetate and washed with 10% citric
acid and brine, the organic phase was concentrated and triturated
with hexane.
[0489] Step 4: Product from step 3 (0.03 mmol) was mixed with
4-nitrophenyl formate (2 equiv.) in 3 mL of DMF, followed by the
addition of DIEA (4 equiv.). The reaction mixture was stirred for 4
hours before was diluted with ethyl acetate. The organic layer was
washed with saturated K.sub.2CO.sub.3, 10% citric acid and water
before it was concentrated to a solid. The solid was treated with
50% TFA in DCM and purified by reverse phase column
chromatography.
Example 10
Synthesis of Compound 152
##STR00258##
[0491] The starting material was made from step 1 to 2 in the
synthesis of compound 123. The starting Boc-protected amide (0.023
mmol) and 3-chloroperoxybenzoic acid (MCPBA, 42.3 mg) were
dissolved in DCM (0.8 mL) and stirred under Ar for 1 hour. The
reaction mixture was diluted with DCM and washed with saturated
Na.sub.2S.sub.2O.sub.3, saturated NaHCO.sub.3 and water. The
organic layer was dried and concentrated to a solid. The solid was
treated with 50% TFA in DCM. The final product was purified by
reverse phase column chromatography.
Example 11
Synthesis of Compound 153
##STR00259## ##STR00260##
[0493] Step 1: Compound 124 (0.29 mmol) was dissolved in 10 mL of
water and then was added N-methyl morpholine (NMM, 2.7 equiv.) and
5 mL of DMF. N-Boc-Gly-Osu (2.2 mmol) in 5 mL DMF was added to the
solution dropwise. The reaction mixture was stirred at room
temperature for 20 minutes before it was concentrated to a
solid.
[0494] Step 2: The product from step 1 was treated with 4 N HCl in
dioxane and purified with reverse phase column chromatography.
Example 12
Synthesis of Compounds 103-105 and 150
##STR00261## ##STR00262##
[0496] Step 1: Bisaniline and carbonyl diimidazole (CDI) were mixed
in dry DMSO (with molar ratio bisaniline:CDI=4:1). The reaction
mixture was stirred at 100.degree. C. for 24 hours. After it cooled
down, water was added to reaction mixture. The precipitate was
filtered and dried under vacuum. The crude product was purified
with silica gel column with dichloromethane and ethyl acetate as
eluents.
[0497] Steps 2 and 3 are similar to steps 2 and 3 of the synthetic
procedure for compound 101.
Example 13
Synthesis of Compound 151
##STR00263##
[0499] Step 1: Bisaniline (4 equiv.) and 1,4-benzenediisocyanate (1
equiv.) were mixed in dry DMSO. The reaction mixture was stirred at
100.degree. C. for 24 hours. After it cooled down, water was added
to the reaction mixture. The precipitate was filtered and dried
under vacuum. The crude product was purified with silica gel column
with dichloromethane and ethyl acetate as eluents.
[0500] Steps 2 and 3 are similar to steps 2 and 3 of the synthetic
procedure for compound 101.
Example 14
Synthesis of Compound 112
##STR00264## ##STR00265##
[0502] 2-Chloro-4,6-dimethoxy-1,3,5-triazine was stirred in
anhydrous THF. N-Methylmorpholine was added. The resulting mixture
was stirred at room temperature for 30 minutes. Then aniline and
pyrimidine-4,6-dicarboxylic acid were added. The mixture was
stirred at room temperature for 24 hours. Then the solvent was
evaporated completely in vacuum. Water was added and the mixture
was stirred for 4 hours. The solid precipitate was collected and
purified by silica gel column with dichloromethane and ethyl
acetate as eluents. The Boc-protected compound was deprotected
using 4N HCl dioxane solution overnight at room temperature to
generate the final product.
Example 15
Synthesis of Compounds 116 and 133-141
[0503] Compound 116 has been synthesized utilizing three synthetic
schemes.
##STR00266##
[0504] Step 1: 8-(dihydroxyboryl)dibenzo[b,d]thiophen-2-ylboronic
acid (4 mmol, 1.08 g) and 3-(3-bromophenyl)propanenitrile (8.8
mmol, 1.875 g) were added into a microwave tube under Argon.
Dioxane (10 mL), Pd(PPh.sub.3).sub.4 (0.4 mmol, 0.46 g) and
K.sub.2CO.sub.3 (16 mmol, 4 mL, 4M) were added. The mixture was
under microwave irradiation (120.degree. C., 15 minutes) with
stirring. Then the reaction was cooled down to room temperature and
extracted with EtOAc and brine. The organic layer was dried over
NaSO.sub.4 and evaporated under vacuum. The residue was purified
with silica column (eluent: EtOAc/hexanes=1/2, v/v). A yellow solid
(1.18 g, 70%) was obtained as product. .sup.1HNMR was
acceptable.
[0505] Step 2: 2,8-di(3-phenylpropanenitrile)benzothiophene (1.33
mmol, 0.59 g) and platinum oxide hydrate (80 mg) were added into a
mixture of MeOH (10 mL)/EtOAC (40 mL). HCl (2 mol, 0.5 mL, 4M in
dioxane) was added. Hydrogen at 60 psi was introduced after removal
of air. The mixture was shacked over night. Then the hydrogen was
removed. The mixture was filtered through celite pad. The filtrate
was evaporated under vacuum. The residue was purified by reverse
phase HPLC. A white solid (70 mg, 12%) was obtained as product.
LC-MS and .sup.1HNMR were acceptable.
##STR00267##
[0506] Step 1, 2 and 3: Synthesis of 2,8-di(tert-butyl
3-phenylpropylcarbamate) benzothiophene. The tert-butyl
3-(3-bromophenyl)propylcarbamate intermediate was synthesized from
3-(3-bromophenyl)propanenitrile by BH.sub.3 reduction and Boc
protection. tert-Butyl 3-(3-bromophenyl)propylcarbamate (2.2 mmol,
0.69 g), 8-(dihydroxyboryl) dibenzo[b,d]thiophen-2-ylboronic acid
(1 mmol, 0.272 g) were added into a microwave tube under Argon.
Dioxane (4 mL), Pd(PPh.sub.3).sub.4 (0.1 mmol, 0.115 g) and
K.sub.2CO.sub.3 (2 mmol, 2 mL, 4M) were added. The mixture was
under microwave irradiation (120.degree. C., 15 minutes) with
stirring. Then the reaction was cooled down to room temperature and
extracted with EtOAc and brine. The organic layer was dried over
NaSO.sub.4 and evaporated under vacuum. The residue was purified
with silica column (eluent: EtOAc/hexanes=1/100-1/2, v/v). A yellow
solid (1.0 g, 76.9%) was obtained as product. .sup.1HNMR was
acceptable.
[0507] Step 4: The yellow solid from above reaction was stirred in
10 ml HCl in dioxane (4
[0508] M) at room temperature overnight. Then the mixture was
filtrated and the cake was washed with ether. The solid was
purified by reverse phase column. A white solid (0.376 g, 46.6%)
was obtained. LC-MS and .sup.1HNMR were acceptable.
##STR00268##
[0509] Intermediate 2,8-di(tert-butyl
3-phenylpropylcarbamate)benzothiophene was synthesized by Suzuki
reaction of 2,8-dibromodibenzothiophene and tert-butyl
3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propylcarbamate,
which was obtained from tert-butyl
3-(3-bromophenyl)propylcarbamate. Compound 116 was obtained
following similar de-protection reaction condition in route 2.
[0510] Compounds 133-141 can be prepared based upon the above
synthesis schemes, as well as the synthesis schemes shown below,
using routine experimentation and knowledge of one skilled in the
art.
##STR00269## ##STR00270## ##STR00271##
##STR00272##
##STR00273##
##STR00274##
##STR00275##
##STR00276##
##STR00277##
##STR00278##
##STR00279##
##STR00280##
Example 16
Synthesis of Compound 106
[0511] Following similar procedure in route 2 of compound 116,
compound 106 was synthesized in 45% overall yield as a white
solid.
Example 17
Synthesis of Compounds 110, 117, 118, 119, 131, and 132
[0512] Following similar procedure in route 3 of compound 116,
compounds 110, 117, 118, 119, 131, and 132 were obtained in 68%,
40%, 20%, 22%, 71%, and 15% overall yield, respectively.
Example 18
Synthesis of Compound 130
[0513] Following similar procedure in route 1 of compound 116,
compound 130 was obtained in 7% overall yield.
Example 19
Synthesis of Compound 120
[0514] 2,8-dibromodibenzo[b,d]furan was synthesized by bromination
in 29% yield. Following similar procedure in route 3, compound 120
was obtained in 69% after two-step reaction.
Example 20
Synthesis of Compounds 154-156
##STR00281## ##STR00282##
[0516] 1.77 gram 2-Chloro-4,6-dimethoxy-1,3,5-triazine was stirred
in anhydrous 50 ml THF. 2.02 gram N-Methylmorpholine was added. The
resulting mixture was stirred at room temperature for 30 minutes.
Then Bis-aniline and salicylic acid were added. The mixture was
stirred at room temperature for 24 hours. Then the solvent was
evaporated completely in vacuum. Water was added and the mixture
was stirred for 4 hours. The solid precipitate was collected and
dried in the vacuum. Then it was purified by crystallization with
DCM and hexane. The Boc-protected compound was deprotected using 4N
HCl dioxane solution overnight at room temperature.
[0517] Compounds 154 and 155 can be prepared based upon the above
synthesis scheme, as well as the two synthesis schemes shown below,
using routine experimentation and knowledge of one skilled in the
art.
##STR00283## ##STR00284## ##STR00285## ##STR00286##
Example 21
Synthesis of Compound 115
##STR00287##
[0519] Compound 115 can be prepared based upon the synthesis scheme
shown below, using routine experimentation and knowledge of one
skilled in the art.
##STR00288##
[0520] Recognizing the significant therapeutic limitations of
peptides, a series of nonpeptidic mimics of these AMPs (SMAMPs)
have been developed that represent a novel and powerful therapy
against many microbes including, for example, malaria. A number of
small molecules, sequence-specific oligomers, and polymers SMAMPs
have been designed herein that have robust in vivo activity against
Staphyococcal aureus in mouse models, suggesting a novel approach
to the development of novel therapeutics. Six of these SMAMPs have
been tested and demonstrated to kill P. falciparum parasites in
culture with a range of IC.sub.50s from 50 nM to 3 .mu.M.
[0521] The present approach has several advantages. Anti-microbial
peptides have remained an effective weapon against bacterial
infection over evolutionary time indicating that their mechanism of
action thwarts bacterial responses that lead to resistance against
toxic substances. This premise is supported by direct experimental
data showing that no appreciable resistance to the action of the
anti-microbial peptides occurs after multiple serial passages of
bacteria in the presence of sub-lethal concentrations of the
peptides. Thus, targeting parasite membranes rather than proteins
represents a highly innovative and novel approach to treating
parasitic diseases and distinguishes the present invention from
most others in this field.
[0522] To more fully evaluate the effects of SMAMP inhibitors on
parasite growth through an entire life cycle, cytotoxic/cytostatic
growth assays are performed. A synchronized population of parasites
can be pulsed with the active SMAMPs for 8 hours during the ring,
trophozoite, or schizont stages. The inhibitors can then removed by
washing parasites and then parasites can be allowed to finish their
cycle. To estimate successful parasite growth, a quantitative
growth assay using luciferase expressing parasites can be used. The
static effects can be differentiated from toxic effects and the
timing of action of these compounds can be determined.
[0523] Morphological phenotypes arising from inhibition can be
determined. All inhibitors can be evaluated using P. falciparum
parasites in a culture model of the erythrocytic cycle. Phenotypes
for all parasite treatments can be analyzed using Giemsa staining
and standard light microscopy. After determining the timing of
parasite death, time lapse DIC/fluorescent microscopy can be used
to determine that after addition of SMAMPs, the plasma membrane
becomes compromised. P. falciparum parasites expressing cytoplasmic
GFP can be used to allow for the visualization of leakage of
cytoplasmic contents after addition of SMAMPs.
[0524] To investigate the potential for parasites to develop
resistance against the antiparasitic activity of the AMP compounds,
P. falciparum can be serially passaged in 0.25.times.EC.sub.50,
0.5.times.EC.sub.50 and the EC.sub.50 concentrations of the top
three AMP compounds. Resulting EC.sub.50 values can be determined
at each passage for each inhibitor. As a control, parallel cultures
can also be exposed to 0.5 EC.sub.50 concentrations of the
antifolate WR99210 and/or pyrimethamine, two well established
anti-parasitic agents for which resistance has been reported. If
parasites that are resistant to SMAMPs are generated, tiling
microarrays (REF) can be used to help determine any genes that
contribute to resistance.
[0525] SMAMPs can be designed that can be used to probe mechanisms
of action and resistance, and compounds that are active in vivo can
be obtained. A very good correlation between the toxicity to
mammalian cells and the overall hydrophobicity of the molecule has
been observed. The activity against a particular bacterium has
correlated with the overall amphiphilicity of the molecule as well
as hydrophobicity, so long as the charge of the molecule was kept
constant.
Example 22
Anti-Protozoan Activity Vs a Malarial Parasite
[0526] Seven compounds with diverse structures were screened in
vitro against the malarial agent Plasmodium falciparum. P.
falciparum is a protozoan parasite and is the infectious agent for
the most prevalent and deadly forms of malaria. It accounts for 80%
of all human malarial infections and 90% of deaths. More than 120
million clinical cases of malaria and between 1 to 1.5 million
deaths occur worldwide every year. There is no vaccine for malaria
and current therapies are plagued by rapid resistance which has
become endemic in certain regions of the world. Several
anti-microbial peptides possess anti-parasitic activities and
appear to kill the parasites by interacting with the plasma
membrane causing excessive permeability, lysis and death.
Specificity for the parasite versus mammalian host cells is
attributed to differences in phospholipid content and the lack of
cholesterol in the protozoan membrane.
[0527] Anti-parasitic activities were measured in vitro using a
human red blood cell assay. A single P. falciparum organism
typically infects an erythrocyte and produces 24 progeny within 48
hours following infection. The progeny are released and rapidly
infect neighboring red blood cells. The seven compounds (Table 1)
were first screened at a single concentration and 6 of the 7
compounds killed P. falciparum progeny at a 10 .mu.M concentration.
Four of the active compounds were tested further to determine
IC.sub.50 and IC.sub.100 values, or minimum concentrations
resulting in 50% and 100% killing, respectively. Observations were
also made during the 48 hour incubation period to assess the
susceptibility of the parasite during lifecycle stages inside and
outside the host erythrocyte. Two compounds, Compound 116 and
Compound 107 possess sub-.mu.M killing activities and Compound 116
potently kills with an IC.sub.50 of 0.05 .mu.M. Observations made
during the infection cycle revealed that only parasitic organisms
inside the erythrocyte were visible in the presence of active
compounds and no extra-cellular organisms were apparent. Together,
these data indicate that the compounds are rapidly killing the
protozoa between the time of release and prior to re-infection. One
goal of targeting parasite membranes, rather than proteins or
metabolic pathways, represents a highly innovative and novel
strategy for treating parasitic diseases and distinguishes this
approach from most others in this field.
TABLE-US-00001 TABLE 1 Susceptibility of P. falciparum to compounds
% Kill IC.sub.50 IC.sub.100 Compound @ 10 .mu.M (.mu.M) (.mu.M) 116
100 0.050 0.850 107 100 0.200 0.850 102 100 1.5 3.5 103 100 0.200
1.5 101 100 NT NT 108 100 NT NT 102 <10 NT NT
Example 23
Anti-Malarial Activity
[0528] Several compounds were screened in cultures of P. falciparum
at a concentration of 1.0 or 1.5 .mu.M and showed strong efficacy.
Of the compounds tested, Compounds 106 and 107 showed the best
results. Compound 106 had an IC.sub.50 in 3D7 cells of 150 nM with
a cytotoxicity of about 40-50 .mu.M in human HepG2 cells. Compound
107 had an IC.sub.50 in 3D7 cells of 275 nM with a cytotoxicity of
about 50-100 .mu.M in human HepG2 cells. Parasite killing generally
took place between 6 to 9 hours (data not shown). Neither compound,
however, was hemolytic as determined by treatment of uninfected red
blood cells using a standard absorbance assay for hemoglobin
release (data not shown). In addition, both compounds disrupted
food vacuoles as assayed by parasites expressing a marker for the
food vacuole (plasmepsin II-YFP), with food vacuole intregrity
measured by standard fluorescence microscopy.
Example 24
Anti-Malarial Activity
[0529] Compounds 106 and 107 were also screened in cultures of P.
falciparum 3D7 and DD2 and compared to chloroquine. Flow cytometry
was used for quantitation of parasitemia using SYOX Green on an
LSRII. The results are shown in Table 2.
TABLE-US-00002 TABLE 2 Compound IC.sub.50 (3D7) IC.sub.50 (DD2)
chloroquine 20 nM 80 nM Compound 107 275 nM 200 nM Compound 106 150
nM 100 nM
The DD2 strain of P. falciparum is 4 times as resistant to
chloroquine as the 3D7 strain. Both Compounds 106 and 107 were
effective in strain DD2. Thus, these compounds are effective in
chloroquire-sensitive and/or chloroquire-resistant strains.
Example 25
Anti-Malarial Activity
[0530] Numerous compounds were initially screened using a high
throughput quantitative parasite growth assay that makes use of a
strain of parasites expressing a cytoplasmic firefly luciferase
(obtained from Dr. Kirk Deitsch, Cornell Medical College). These
parasites were transfected with a vector containing the firefly
luciferase gene using the malarial HRPII promoter. To grow
parasites, culture dishes ranging from 96 well plates to 30 ml
dishes were used. The 3D7 strain of P. falciparum for assays and
transfections was primarily used because it has become the standard
chloroquine sensitive reference strain and was used for the genome
sequencing project. Parasites were cultured in human RBCs under an
atmosphere of 5% O.sub.2/7% CO.sub.2/88% N.sub.2 in RPMI 1640
medium supplemented with 25 mM Hepes, 30 mg/L hypoxanthine, 0.225%
(w/v) NaHCO.sub.3 and 0.5% (w/v) Albumax II (Life Technologies,
Grand Island, N.Y.). Parasite growth was normally synchronized by a
combination of serial D-sorbitol treatment for selection of ring
stage parasites followed by selective purification of mature
schizonts using a Super Macs II magnetic separator (Miltenyi
Biotec).
[0531] A standard luminescent readout was used to measure the
growth of parasites. Parasites were grown under normal conditions,
lysed in the presence of the luminescence reagents (Bright Glo,
Promega) and then measured. To initially test for growth,
luciferase expressing parasites were synchronized using serial
sorbitol treatments and then parasitemia, the percentage of RBCS
infected with parasites, was adjusted using uninfected RBCs. 100
.mu.l of total media was used in a 96 well format. Parasitized RBCs
were incubated in 96 well plates at 37.degree. C. and gassed with
5% CO.sub.2, 5% O.sub.2, 90% N.sub.2. Parasites were allowed to
grow for approximately 60 hours, until they successfully divided,
ruptured and reinvaded new RBCs. At 10-15 hours post invasion, the
cells were lysed, and luciferase levels were measured using an
Analyst HT luminometer (Molecular Devices). Results are shown in
Table 3.
TABLE-US-00003 TABLE 3 Compound IC.sub.50 .mu.M Artesunate 0.009
Compound 106 1.153 Compound 118 0.364 Compound 119 1.858 Compound
110 0.584 Compound 117 0.301 Compound 104 >10 Compound 111 0.587
Compound 113 0.241 Compound 112 >10 Compound 120 0.604 Compound
121 1.505 Compound 114 >10 Compound 102 5.376 Compound 103 0.783
Compound 107 0.314 Compound 116 0.318 Compound 101 0.308 Compound
122 0.260 Compound 123 1.366 Compound 124 1.582 Compound 129 0.832
Compound 128 1.725 Compound 127 1.765 Compound 126 1.420 Compound
125 0.286 Compound 130 2.559 Compound 131 0.235 Compound 132 0.236
Compound 133 2.028 Compound 134 2.438 Compound 135 0.108 Compound
136 0.958 Compound 137 0.604 Compound 138 0.213 Compound 139 1.169
Compound 140 1.674 Compound 142 0.063 Compound 154 0.200 Compound
149 0.357 Compound 141 1.344 Compound 143 0.258 Compound 144 3.399
Compound 145 0.369 Compound 146 0.127 Compound 155 0.535 Compound
152 0.783 Compound 153 0.925 Compound 150 6.608 Compound 151 2.784
Compound 147 0.221 Compound 148 0.704 Compound 156 0.107
[0532] Various modifications of the invention, in addition to those
described herein, will be apparent to those skilled in the art from
the foregoing description. Such modifications are also intended to
fall within the scope of the appended claims. Each reference
(including, but not limited to, journal articles, U.S. and non-U.S.
patents, patent application publications, international patent
application publications, gene bank accession numbers, and the
like) cited in the present application is incorporated herein by
reference in its entirety.
* * * * *